Skip to Content

'
Wai-Kwan Alfred Yung, M.D.

Present Title & Affiliation

Primary Appointment

Professor, Department of Neuro-Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX
Senior Advisor, Brain Tumor Center, The University of Texas MD Anderson Cancer Center, Houston, TX

Bio Statement

Dr. Wai-Kwan Alfred Yung is a Professor of Neuro-Oncology and Cancer Biology, as well as the Margaret and Ben Love Chair of Clinical Cancer Care. He has served as Chair of the Department of Neuro-Oncology since 1999. He is also the director of the Brain Tumor SPORE and co-director of the Brain Tumor Center at MD Anderson. Dr. Yung has extensive experience and expertise in the field of brain tumor research.  His research program spans more than two decades and includes basic, translational, and clinical research. Along with 28 years of continuous funding by NCI, his work has also been funded by foundations and industry grants. The overall objective of his research program is to develop new therapeutic approaches to block the regulatory mechanisms of brain cancer cells. His primary research interest focuses on development of molecular therapeutic strategies targeting the EGFR and PTEN/PI3 kinase pathways and their parallel regulatory mechanisms that are crucial to human glioma genesis and progression. The translational research effort has included the development of oncolytic adenoviral vectors and pre-clinical studies of many small molecular inhibitors targeting the PTEN/P13K and EGFR pathways. Dr. Yung has published over 300 peer-reviewed articles in many high impact journals covering diverse laboratory and clinical research topics. He serves on the scientific advisory board ofseveral pharmaceutical companies and private foundations.  He is the current editor-in-chief of Neuro-Oncology and co-chair of the NCI Brain Malignancy Steering Committee.


Education & Training

Degree-Granting Education

1975 University of Chicago, Chicago, IL, MD, Medicine
1971 University of Minnesota, Minneapolis, MN, BS, Biochemistry

Postgraduate Training

1978-1981 Fellowship, Neuro-Oncology, Memorial Sloan-Kettering Cancer Center, NY, NY
1978-1979 Chief Resident, Neurology, Memorial Sloan-Kettering Cancer Center, NY, NY
1975 Residency, Neurology, University of California, San Diego, CA

Board Certifications

1/1980 American Board of Psychiatry and Neurology

Experience/Service

Other Appointments/Responsibilities

Co-Chair, NCI Brain Malignancies Steering Committee, Rockville, MD, 2010-present

Consultantships

Advisory Board Member, Merck & Company, North Wales, PA, 2010-present
Actelion, Basel Switzerland, 2010-2015
Consultant, Terry Fox Research Institute, Vancouver, BC, Canada, 2009-present
Consultant, The National Brain Tumor Society, Boston, MA, 2009-present
Scientific Advisory Board, Eden Therapeutics Inc., Cambridge, MA, 2008-2013
Scientific Advisory Board, DNAtrix, Houston TX, 2005-present

Institutional Committee Activities

Member, Enhancing Industry Partnership Working Group, 2013-present
Member, Molecular Testing Evaluation Committee, 2010-present
Member, Institute of Personalized Cancer Therapy (IPCT) Committee, 2009-present
Member, Experimental Diagnostic Imaging Search Committee, 5/2008-2009
Member, Search Committee, Department of Neurosurgery, 2008-present
Member, Division of Cancer Medicine CTRC Steering Committee, 2006-2015
Member: 2005-2012, Chair: 2009-2012, Global Academic Oversight Steering Committee, 2005-2012
Chair, Multidisciplinary Research Advisory Committee, 2002-2014
Member, Oversight Panel for the Institutional Research Grants Committee, 2002-2012
Member, Institutional Research Executive Committee, 2000-present
Member, Brain and Spine Center Operations Committee, 2000-2015
Co-Chair, Brain Tumor Center Executive Committee, 1999-present

Honors and Awards

2016-present Invited Member, Blue Ribbon Panel for National Cancer Moonshot Initiative, National Cancer Institute/National Institutes of Health
2015 NBTS Founders Award
2015 Pritzher School of Medicine Alumni Distinguish Service Award, University of Chicago
2009-present Who's Who in America
2007-present Who's Who in the South and Southwest
1992-present Best Doctors in America 2013

Professional Memberships

American Academy of Neurology
Member, 1988-present
American Association for Cancer Research
Member, 1998-present
American Association for the Advancement of Science
Member, 1998-present
American Society of Clinical Oncology
Program Chair, 1997-1999
Blue Ribbon Panel for National Cancer Moonshot Initiative (NCI/NIH), Washington, DC
Invited Member, 2016-present
Society for Neuro-Oncology
Member, 1994-present

Selected Publications

Peer-Reviewed Original Research Articles

1. Raizer JJ, Giglio P, Hu J, Groves M, Merrell R, Conrad C, Phuphanich S, Puduvalli VK, Loghin M, Paleologos N, Yuan Y, Liu D, Rademaker A, Yung WK, Vaillant B, Rudnick J, Chamberlain M, Vick N, Grimm S, Tremont-Lukats IW, De Groot J, Aldape K, Gilbert MR, Brain Tumor Trials Collaborative. A phase II study of bevacizumab and erlotinib after radiation and temozolomide in MGMT unmethylated GBM patients. J Neurooncol. e-Pub 10/17/2015. PMID: 26476729.
2. Kim SJ, Lee HJ, Kim MS, Choi HJ, He J, Wu Q, Aldape K, Weinberg JS, Yung WK, Conrad CA, Langley RR, Lehembre F, Regenass U, Fidler IJ. Macitentan, a Dual Endothelin Receptor Antagonist, in Combination with Temozolomide Leads to Glioblastoma Regression and Long-term Survival in Mice. Clin Cancer Res 21(20):4630-41, 10/15/2015. e-Pub 6/23/2015. PMID: 26106074.
3. Liu Q, Liu Y, Li W, Wang X, Sawaya R, Lang FF, Yung WK, Chen K, Fuller GN, Zhang W. Genetic, epigenetic, and molecular landscapes of multifocal and multicentric glioblastoma. Acta Neuropathol 130(4):587-97, 10/2015. e-Pub 9/1/2015. PMID: 26323991.
4. Sun Jin Kim ; Ho Jeong Lee ; Mark Seungwook Kim ; Hyun Jin Choi ; Junqin He ; Qiuyu Wu ; Kenneth Aldape ; Jeffrey S. Weinberg ; W. K Alfred Yung ; Charles A. Conrad ; Robert R. Langley ; François Lehembre ; Urs Regenass ; Isaiah J. Fidler. Macitentan, a dual endothelin receptor antagonist, in combination with temozolomide leads to glioblastoma regression and long-term survival in mice 21(20):4630-4641, 10/2015.
5. Ellingson BM, Bendszus M, Boxerman J, Barboriak D, Erickson BJ, Smits M, Nelson SJ, Gerstner E, Alexander B, Goldmacher G, Wick W, Vogelbaum M, Weller M, Galanis E, Kalpathy-Cramer J, Shankar L, Jacobs P, Pope WB, Yang D, Chung C, Knopp MV, Cha S, van den Bent MJ, Chang S, Yung WK, Cloughesy TF, Wen PY, Gilbert MR, Jumpstarting Brain Tumor Drug Development Coalition Imaging Standardization Steering Committee. Consensus recommendations for a standardized Brain Tumor Imaging Protocol in clinical trials. Neuro Oncol 17(9):1188-98, 9/2015. e-Pub 8/5/2015. PMCID: PMC4588759.
6. Cancer Genome Atlas Research Network, Brat DJ, Verhaak RG, Aldape KD, Yung WK, Salama SR, Cooper LA, Rheinbay E, Miller CR, Vitucci M, Morozova O, Robertson AG, Noushmehr H, Laird PW, Cherniack AD, Akbani R, Huse JT, Ciriello G, Poisson LM, Barnholtz-Sloan JS, Berger MS, Brennan C, Colen RR, Colman H, Flanders AE, Giannini C, Grifford M, Iavarone A, Jain R, Joseph I, Kim J, Kasaian K, Mikkelsen T, Murray BA, O'Neill BP, Pachter L, Parsons DW, Sougnez C, Sulman EP, Vandenberg SR, Van Meir EG, von Deimling A, Zhang H, Crain D, Lau K, Mallery D, Morris S, Paulauskis J, Penny R, Shelton T, Sherman M, Yena P, Black A, Bowen J, Dicostanzo K, Gastier-Foster J, Leraas KM, Lichtenberg TM, Pierson CR, Ramirez NC, Taylor C, Weaver S, Wise L, Zmuda E, Davidsen T, Demchok JA, Eley G, Ferguson ML, Hutter CM, Mills Shaw KR, Ozenberger BA, Sheth M, Sofia HJ, Tarnuzzer R, Wang Z, Yang L, Zenklusen JC, Ayala B, Baboud J, Chudamani S, Jensen MA, Liu J, Pihl T, Raman R, Wan Y, Wu Y, Ally A, Auman JT, Balasundaram M, Balu S, Baylin SB, Beroukhim R, Bootwalla MS, Bowlby R, Bristow CA, Brooks D, Butterfield Y, Carlsen R, Carter S, Chin L, Chu A, Chuah E, Cibulskis K, Clarke A, Coetzee SG, Dhalla N, Fennell T, Fisher S, Gabriel S, Getz G, Gibbs R, Guin R, Hadjipanayis A, Hayes DN, Hinoue T, Hoadley K, Holt RA, Hoyle AP, Jefferys SR, Jones S, Jones CD, Kucherlapati R, Lai PH, Lander E, Lee S, Lichtenstein L, Ma Y, Maglinte DT, Mahadeshwar HS, Marra MA, Mayo M, Meng S, Meyerson ML, Mieczkowski PA, Moore RA, Mose LE, Mungall AJ, Pantazi A, Parfenov M, Park PJ, Parker JS, Perou CM, Protopopov A, Ren X, Roach J, Sabedot TS, Schein J, Schumacher SE, Seidman JG, Seth S, Shen H, Simons JV, Sipahimalani P, Soloway MG, Song X, Sun H, Tabak B, Tam A, Tan D, Tang J, Thiessen N, Triche T, Van Den Berg DJ, Veluvolu U, Waring S, Weisenberger DJ, Wilkerson MD, Wong T, Wu J, Xi L, Xu AW, Yang L, Zack TI, Zhang J, Aksoy BA, Arachchi H, Benz C, Bernard B, Carlin D, Cho J, DiCara D, Frazer S, Fuller GN, Gao J. Comprehensive, Integrative Genomic Analysis of Diffuse Lower-Grade Gliomas. N Engl J Med 372(26):2481-98, 6/25/2015. e-Pub 6/10/2015. PMCID: PMC4530011.
7. Turner KM, Sun Y, Ji P, Granberg KJ, Bernard B, Hu L, Cogdell DE, Zhou X, Yli-Harja O, Nykter M, Shmulevich I, Yung WK, Fuller GN, Zhang W. Genomically amplified Akt3 activates DNA repair pathway and promotes glioma progression. Proc Natl Acad Sci U S A 112(11):3421-6, 3/17/2015. e-Pub 3/3/2015. PMCID: PMC4371922.
8. Pachella LA, Kamiya-Matsuoka C, Lee EL, Olar A, Yung WK. Supratentorial extraventricular anaplastic ependymoma with extracranial metastasis. J Clin Neurosci 22(3):605-7, 3/2015. e-Pub 10/31/2014. PMCID: PMC4385743.
9. Alexander BM, Galanis E, Yung WK, Ballman KV, Boyett JM, Cloughesy TF, Degroot JF, Huse JT, Mann B, Mason W, Mellinghoff IK, Mikkelsen T, Mischel PS, O'Neill BP, Prados MD, Sarkaria JN, Tawab-Amiri A, Trippa L, Ye X, Ligon KL, Berry DA, Wen PY. Brain Malignancy Steering Committee clinical trials planning workshop: Report from the Targeted Therapies Working Group. Neuro Oncol 17(2):180-8, 2/2015. e-Pub 8/26/2014. PMCID: PMC4288520.
10. Penas-Prado M, Hess KR, Fisch MJ, Lagrone LW, Groves MD, Levin VA, De Groot JF, Puduvalli VK, Colman H, Volas-Redd G, Giglio P, Conrad CA, Salacz ME, Floyd JD, Loghin ME, Hsu SH, Gonzalez J, Chang EL, Woo SY, Mahajan A, Aldape KD, Yung WK, Gilbert MR, MD Anderson Community Clinical Oncology Program, Brain Tumor Trials Collaborative. Randomized phase II adjuvant factorial study of dose-dense temozolomide alone and in combination with isotretinoin, celecoxib, and/or thalidomide for glioblastoma. Neuro Oncol 17(2):266-73, 2/2015. e-Pub 9/19/2014. PMCID: PMC4288521.
11. Dimpy Koul ; Jun Yao ; Shuzhen Wang ; Ying Yuan ; Erik Sulman ; Frederick Lang ; W. K Alfred Yung ; Howard Colman. Erratum: Retraction: Novel HSP90 Inhibitor NVP-HSP990 targets cell-cycle regulators to ablate olig 2-positive glioma tumor-initiating cells. Cancer Research 74(22):6731-6732, 11/2014.
12. Mandel, J. J., Yust-Katz, S., Cachia, D., Wu, J., Liu, D., de Groot, J. F., Yung, A. W. K. & Gilbert, M. R. Leptomeningeal dissemination in glioblastoma; an inspection of risk factors, treatment, and outcomes at a single institution. Journal of Neuro-Oncology 120(3):597-605, 11/2014.
13. Wen PY, Cloughesy TF, Ellingson BM, Reardon DA, Fine HA, Abrey L, Ballman K, Bendszuz M, Buckner J, Chang SM, Prados MD, Pope WB, Gregory Sorensen A, van den Bent M, Yung WK. Report of the Jumpstarting Brain Tumor Drug Development Coalition and FDA clinical trials neuroimaging endpoint workshop (January 30, 2014, Bethesda MD). Neuro Oncol 16(suppl 7):vii36-vii47, 10/2014. PMCID: PMC4195530.
14. Desai S, Ding M, Wang B, Lu Z, Zhao Q, Shaw K, Yung WK, Weinstein JN, Tan M, Yao J. Tissue-specific isoform switch and DNA hypomethylation of the pyruvate kinase PKM gene in human cancers. Oncotarget 5(18):8202-10, 9/30/2014. e-Pub 8/2013. PMCID: PMC4226677.
15. Weiwei Yang ; Yan Xia ; David Hawke ; Xinjian Li ; Ji Liang ; Dongming Xing ; Kenneth Aldape ; Tony Hunter ; W. K Alfred Yung ; Zhimin Lu. Erratum: PKM2 phosphorylates histone H3 and promotes gene transcription and tumorigenesis. Cell 158(5):1210, 8/2014.
16. Hamza MA, Mandel JJ, Conrad CA, Gilbert MR, Yung WK, Puduvalli VK, DeGroot JF. Survival outcome of early versus delayed bevacizumab treatment in patients with recurrent glioblastoma. J Neurooncol 119(1):135-40, 8/2014. e-Pub 5/7/2014. PMCID: PMC4297475.
17. Wen PY, Chang SM, Lamborn KR, Kuhn JG, Norden AD, Cloughesy TF, Robins HI, Lieberman FS, Gilbert MR, Mehta MP, Drappatz J, Groves MD, Santagata S, Ligon AH, Yung WK, Wright JJ, Dancey J, Aldape KD, Prados MD, Ligon KL. Phase I/II study of erlotinib and temsirolimus for patients with recurrent malignant gliomas: North American Brain Tumor Consortium trial 04-02. Neuro Oncol 16(4):567-78, 4/2014. e-Pub 1/26/2014. PMCID: PMC3956354.
18. Yao J, Caballero OL, Yung WK, Weinstein JN, Riggins GJ, Strausberg RL, Zhao Q. Tumor subtype-specific cancer-testis antigens as potential biomarkers and immunotherapeutic targets for cancers. Cancer Immunol Res 2(4):371-9, 4/2014. e-Pub 11/25/2013. PMCID: PMC4007352.
19. Peng Z, Maxwell D, Sun D, Ying Y, Schuber PT, Bhanu Prasad BA, Gelovani J, Yung WK, Bornmann WG. Design and Synthesis of an Inositol Phosphate Analog Based on Computational Docking Studies. Tetrahedron 70(4):984-990, 1/28/2014. PMCID: PMC4125022.
20. Saito N, Fu J, Zheng S, Yao J, Wang S, Liu DD, Yuan Y, Sulman EP, Lang FF, Colman H, Verhaak RG, Yung WK, Koul D. A high Notch pathway activation predicts response to γ secretase inhibitors in proneural subtype of glioma tumor initiating cells. Stem Cells 32(1):301-12, 1/2014. e-Pub 8/27/2013. PMCID: PMC3947402.
21. Jiang H, Clise-Dwyer K, Ruisaard KE, Fan X, Tian W, Gumin J, Lamfers ML, Kleijn A, Lang FF, Yung WK, Vence LM, Gomez-Manzano C, Fueyo J. Delta-24-RGD oncolytic adenovirus elicits anti-glioma immunity in an immunocompetent mouse model. PLoS One 9(5):e97407, 2014. e-Pub 5/2014. PMCID: PMC4020829.
22. Guan X, Vengoechea J, Zheng S, Sloan AE, Chen Y, Brat DJ, O'Neill BP, de Groot J, Yust-Katz S, Yung WK, Cohen ML, Aldape KD, Rosenfeld S, Verhaak RG, Barnholtz-Sloan JS. Molecular subtypes of glioblastoma are relevant to lower grade glioma. PLoS One 9(3):e91216, 2014. e-Pub 3/10/2014. PMCID: PMC3948818.
23. Qun Liu ; Kristen M. Turner ; W. K Alfred Yung ; Kexin Chen ; Wei Zhang. Role of AKT signaling in DNA repair and clinical response to cancer therapy. Neuro-Oncology 16(10):1313-1323, 2014.
24. Mohamed A. Hamza ; Jacob J. Mandel ; Charles A. Conrad ; Mark R. Gilbert ; W. K Alfred Yung ; Vinay K. Puduvalli ; John F. DeGroot. Survival outcome of early versus delayed bevacizumab treatment in patients with recurrent glioblastoma. Journal of Neuro-Oncology 119(1):135-140, 2014.
25. Shruti Desai ; Minming Ding ; Bin Wang ; Zhimin Lu ; Qi Zhao ; Kenna Shaw ; W. K. Alfred Yung ; John N. Weinstein ; Ming Tan ; Jun Yao. Tissue-specific isoform switch and DNA hypomethylation of the pyruvate kinase PKM gene in human cancers. Oncotarget 5(18):8202-8210, 2014.
26. Brennan CW, Verhaak RG, McKenna A, Campos B, Noushmehr H, Salama SR, Zheng S, Chakravarty D, Sanborn JZ, Berman SH, Beroukhim R, Bernard B, Wu CJ, Genovese G, Shmulevich I, Barnholtz-Sloan J, Zou L, Vegesna R, Shukla SA, Ciriello G, Yung WK, Zhang W, Sougnez C, Mikkelsen T, Aldape K, Bigner DD, Van Meir EG, Prados M, Sloan A, Black KL, Eschbacher J, Finocchiaro G, Friedman W, Andrews DW, Guha A, Iacocca M, O'Neill BP, Foltz G, Myers J, Weisenberger DJ, Penny R, Kucherlapati R, Perou CM, Hayes DN, Gibbs R, Marra M, Mills GB, Lander E, Spellman P, Wilson R, Sander C, Weinstein J, Meyerson M, Gabriel S, Laird PW, Haussler D, Getz G, Chin L, TCGA Research Network. The somatic genomic landscape of glioblastoma. Cell 155(2):462-77, 10/10/2013. PMCID: PMC3910500.
27. John N. Weinstein ; Eric A. Collisson ; Gordon B. Mills ; Kenna R Mills Shaw ; Brad A. Ozenberger ; Kyle Ellrott ; Chris Sander ; Joshua M. Stuart ; Kyle Chang ; Chad J. Creighton ; Caleb Davis ; Lawrence Donehower ; Jennifer Drummond ; David Wheeler ; Adrian Ally ; Miruna Balasundaram ; Inanc Birol ; Yaron S N Butterfield ; Andy Chu ; Eric Chuah ; Hye Jung E Chun ; Noreen Dhalla ; Ranabir Guin ; Martin Hirst ; Carrie Hirst ; Robert A. Holt ; Steven J M Jones ; Darlene Lee ; Haiyan I. Li ; Marco A. Marra ; Michael Mayo ; Richard A. Moore ; Andrew J. Mungall ; A. Gordon Robertson ; Jacqueline E. Schein ; Payal Sipahimalani ; Angela Tam ; Nina Thiessen ; Richard J. Varhol ; Rameen Beroukhim ; Ami S. Bhatt ; Angela N. Brooks ; Andrew D. Cherniack ; Samuel S. Freeman ; Stacey B. Gabriel ; Elena Helman ; Joonil Jung ; Matthew Meyerson ; Akinyemi I. Ojesina ; Chandra Sekhar Pedamallu ; Gordon Saksena ; Steven E. Schumacher ; Barbara Tabak ; Travis Zack ; Eric S. Lander ; Christopher A. Bristow ; Angela Hadjipanayis ; Psalm Haseley ; Raju Kucherlapati ; Semin Lee ; Eunjung Lee ; Lovelace J. Luquette ; Harshad S. Mahadeshwar ; Angeliki Pantazi ; Michael Parfenov ; Peter J. Park ; Alexei Protopopov ; Xiaojia Ren ; Netty Santoso ; Jonathan Seidman ; Sahil Seth ; Xingzhi Song ; Jiabin Tang ; Ruibin Xi ; Andrew W. Xu ; Lixing Yang ; Dong Zeng ; J. Todd Auman ; Saianand Balu ; Elizabeth Buda ; Cheng Fan ; Katherine A. Hoadley ; Corbin D. Jones ; Shaowu Meng ; Piotr A. Mieczkowski ; Joel S. Parker ; Charles M. Perou ; Jeffrey Roach ; Yan Shi ; Grace O. Silva ; Donghui Tan ; Umadevi Veluvolu ; Scot Waring ; Matthew D. Wilkerson ; Junyuan Wu ; Wei Zhao ; Tom Bodenheimer ; D. Neil Hayes ; Alan P. Hoyle ; Stuart R. Jeffreys ; Lisle E. Mose ; Janae V. Simons ; Mathew G. Soloway ; Stephen B. Baylin ; Benjamin P. Berman ; Moiz S. Bootwalla ; Ludmila Danilova ; James G. Herman ; Toshinori Hinoue ; Peter W. Laird ; Suhn K. Rhie ; Hui Shen ; Timothy Triche ; Daniel J. Weisenberger ; Scott. The cancer genome atlas pan-cancer analysis project. Nature Genetics 45(10):1113-1120, 10/2013.
28. Anderson MD, Theeler BJ, Penas-Prado M, Groves MD, Yung WK. Bevacizumab use in disseminated choroid plexus papilloma. J Neurooncol 114(2):251-3, 9/2013. e-Pub 6/13/2013. PMID: 23761024.
29. Zhang C, Moore LM, Li X, Yung WK, Zhang W. IDH1/2 mutations target a key hallmark of cancer by deregulating cellular metabolism in glioma. Neuro Oncol 15(9):1114-26, 9/2013. e-Pub 7/21/2013. PMCID: PMC3748922.
30. Yust-Katz S, Liu D, Yuan Y, Liu V, Kang S, Groves M, Puduvalli V, Levin V, Conrad C, Colman H, Hsu S, Yung WK, Gilbert MR. Phase 1/1b study of lonafarnib and temozolomide in patients with recurrent or temozolomide refractory glioblastoma. Cancer 119(15):2747-53, 8/1/2013. e-Pub 4/30/2013. PMCID: PMC4001735.
31. Weller M, Yung WK. Angiogenesis inhibition for glioblastoma at the edge: beyond AVAGlio and RTOG 0825. Neuro Oncol 15(8):971, 8/2013. PMCID: PMC3714162.
32. Alexander BM, Wen PY, Trippa L, Reardon DA, Yung WK, Parmigiani G, Berry DA. Biomarker-based adaptive trials for patients with glioblastoma--lessons from I-SPY 2. Neuro Oncol 15(8):972-8, 8/2013. e-Pub 7/14/2013. PMCID: PMC3714161.
33. Zheng S, Fu J, Vegesna R, Mao Y, Heathcock LE, Torres-Garcia W, Ezhilarasan R, Wang S, McKenna A, Chin L, Brennan CW, Yung WK, Weinstein JN, Aldape KD, Sulman EP, Chen K, Koul D, Verhaak RG. A survey of intragenic breakpoints in glioblastoma identifies a distinct subset associated with poor survival. Genes Dev 27(13):1462-72, 7/1/2013. e-Pub 6/24/2013. PMCID: PMC3713427.
34. Kim YW, Koul D, Kim SH, Lucio-Eterovic AK, Freire PR, Yao J, Wang J, Almeida JS, Aldape K, Yung WK. Identification of prognostic gene signatures of glioblastoma: a study based on TCGA data analysis. Neuro Oncol 15(7):829-39, 7/2013. e-Pub 3/15/2013. PMCID: PMC3688008.
35. Shonka N, Piao Y, Gilbert M, Yung A, Chang S, DeAngelis LM, Lassman AB, Liu J, Cloughesy T, Robins HI, Lloyd R, Chen A, Prados M, Wen PY, Heymach J, de Groot J. Cytokines associated with toxicity in the treatment of recurrent glioblastoma with aflibercept. Target Oncol 8(2):117-25, 6/2013. e-Pub 1/24/2013. PMID: 23345034.
36. Fu J, Koul D, Yao J, Wang S, Yuan Y, Colman H, Sulman EP, Lang FF, Yung WK. Novel HSP90 inhibitor NVP-HSP990 targets cell cycle regulators to ablate Olig2-positive glioma tumor initiating cells. Cancer Res 73(10):3062-74, 5/15/2013. e-Pub 3/14/2013. PMCID: PMC3655088.
37. Zhao Q, Caballero OL, Davis ID, Jonasch E, Tamboli P, Yung WK, Weinstein JN, Kenna Shaw for TCGA research network, Strausberg RL, Yao J. Tumor-specific isoform switch of the fibroblast growth factor receptor 2 underlies the mesenchymal and malignant phenotypes of clear cell renal cell carcinomas. Clin Cancer Res 19(9):2460-72, 5/1/2013. e-Pub 2/26/2013. PMCID: PMC3644028.
38. Yung WK. From GWAS risk foci to glioma molecular subclass. Neuro Oncol 15(5):513-4, 5/2013. PMCID: PMC3635527.
39. Alexander BM, Wang M, Yung WK, Fine HA, Donahue BA, Tremont IW, Richards RS, Kerlin KJ, Hartford AC, Curran WJ, Mehta MP. A phase II study of conventional radiation therapy and thalidomide for supratentorial, newly-diagnosed glioblastoma (RTOG 9806). J Neurooncol 111(1):33-9, 1/2013. e-Pub 10/20/2012. PMID: 23086432.
40. W. K Alfred Yung. Neuro-oncology. Neuro-Oncology 15(12):1591-1594, 2013.
41. W. K Alfred Yung. Neuro-oncology: Past milestones and the journey ahead. Neuro-Oncology 15(11):1453-1454, 2013.
42. Lee EQ, Kuhn J, Lamborn KR, Abrey L, DeAngelis LM, Lieberman F, Robins HI, Chang SM, Yung WK, Drappatz J, Mehta MP, Levin VA, Aldape K, Dancey JE, Wright JJ, Prados MD, Cloughesy TF, Gilbert MR, Wen PY. Phase I/II study of sorafenib in combination with temsirolimus for recurrent glioblastoma or gliosarcoma: North American Brain Tumor Consortium study 05-02. Neuro Oncol 14(12):1511-8, 12/2012. e-Pub 10/24/2012. PMCID: PMC3499017.
43. Lee EQ, Puduvalli VK, Reid JM, Kuhn JG, Lamborn KR, Cloughesy TF, Chang SM, Drappatz J, Yung WK, Gilbert MR, Robins HI, Lieberman FS, Lassman AB, McGovern RM, Xu J, Desideri S, Ye X, Ames MM, Espinoza-Delgado I, Prados MD, Wen PY. Phase I Study of Vorinostat in Combination with Temozolomide in Patients with High-Grade Gliomas: North American Brain Tumor Consortium Study 04-03. Clin Cancer Res 18(21):6032-9, 11/1/2012. e-Pub 8/24/2012. PMCID: PMC3947570.
44. Theeler BJ, Yung WK, Fuller GN, De Groot JF. Moving toward molecular classification of diffuse gliomas in adults. Neurology 79(18):1917-26, 10/30/2012. PMCID: PMC3525311.
45. Yung WK. New impact factor reflects increased quality. Neuro Oncol 14(9):1115, 9/2012. PMCID: PMC3424218.
46. Weiwei Yang ; Yan Xia ; David Hawke ; Xinjian Li ; Ji Liang ; Dongming Xing ; Kenneth Aldape ; Tony Hunter ; W. K. Alfred Yung ; Zhimin Lu. PKM2 phosphorylates histone H3 and promotes gene transcription and tumorigenesis. Cell 150(4):685-696, 8/2012.
47. Giglio P, Dhamne M, Hess KR, Gilbert MR, Groves MD, Levin VA, Kang SL, Ictech SE, Liu V, Colman H, Conrad CA, Loghin M, de Groot J, Yung WK, Puduvalli VK. Phase 2 trial of irinotecan and thalidomide in adults with recurrent anaplastic glioma. Cancer 118(14):3599-606, 7/15/2012. e-Pub 11/15/2011. PMID: 22086614.
48. Whitney B. Pope ; Xin Joe Qiao ; Hyun J. Kim ; Albert Lai ; Phioanh Nghiemphu ; Xi Xue ; Benjamin M. Ellingson ; David Schiff ; Dawit Aregawi ; Soonmee Cha ; Vinay K. Puduvalli ; Jing Wu ; Wai Kwan A Yung ; Geoffrey S. Young ; James Vredenburgh ; Dan Barboriak ; Lauren E. Abrey ; Tom Mikkelsen ; Rajan Jain ; Nina A. Paleologos ; Patricia Lada Rn ; Michael Prados ; Jonathan Goldin ; Patrick Y. Wen ; Timothy Cloughesy. Apparent diffusion coefficient histogram analysis stratifies progression-free and overall survival in patients with recurrent GBM treated with bevacizumab: A multi-center study. Journal of Neuro-Oncology 108(3):491-498, 7/2012.
49. Wen PY, Lee EQ, Reardon DA, Ligon KL, Alfred Yung WK. Current clinical development of PI3K pathway inhibitors in glioblastoma. Neuro Oncol 14(7):819-29, 7/2012. e-Pub 5/22/2012. PMCID: PMC3379803.
50. Reardon DA, Conrad CA, Cloughesy T, Prados MD, Friedman HS, Aldape KD, Mischel P, Xia J, DiLea C, Huang J, Mietlowski W, Dugan M, Chen W, Yung WK. Phase I study of AEE788, a novel multitarget inhibitor of ErbB- and VEGF-receptor-family tyrosine kinases, in recurrent glioblastoma patients. Cancer Chemother Pharmacol 69(6):1507-18, 6/2012. e-Pub 3/7/2012. PMCID: PMC4351868.
51. Vivanco I, Robins HI, Rohle D, Campos C, Grommes C, Nghiemphu PL, Kubek S, Oldrini B, Chheda MG, Yannuzzi N, Tao H, Zhu S, Iwanami A, Kuga D, Dang J, Pedraza A, Brennan CW, Heguy A, Liau LM, Lieberman F, Yung WK, Gilbert MR, Reardon DA, Drappatz J, Wen PY, Lamborn KR, Chang SM, Prados MD, Fine HA, Horvath S, Wu N, Lassman AB, DeAngelis LM, Yong WH, Kuhn JG, Mischel PS, Mehta MP, Cloughesy TF, Mellinghoff IK. Differential Sensitivity of Glioma- versus Lung Cancer-Specific EGFR Mutations to EGFR Kinase Inhibitors. Cancer Discov 2(5):458-471, 5/2012. e-Pub 3/31/2012. PMCID: PMC3354723.
52. Sai K, Wang S, Balasubramaniyan V, Conrad C, Lang FF, Aldape K, Szymanski S, Fokt I, Dasgupta A, Madden T, Guan S, Chen Z, Alfred Yung WK, Priebe W, Colman H. Induction of cell-cycle arrest and apoptosis in glioblastoma stem-like cells by WP1193, a novel small molecule inhibitor of the JAK2/STAT3 pathway. J Neurooncol 107(3):487-501, 5/2012. e-Pub 1/17/2012. PMID: 22249692.
53. Reardon DA, Wen PY, Alfred Yung WK, Berk L, Narasimhan N, Turner CD, Clackson T, Rivera VM, Vogelbaum MA. Ridaforolimus for patients with progressive or recurrent malignant glioma: a perisurgical, sequential, ascending-dose trial. Cancer Chemother Pharmacol 69(4):849-60, 4/2012. e-Pub 10/30/2011. PMID: 22037923.
54. Pope WB, Qiao XJ, Kim HJ, Lai A, Nghiemphu P, Xue X, Ellingson BM, Schiff D, Aregawi D, Cha S, Puduvalli VK, Wu J, Yung WK, Young GS, Vredenburgh J, Barboriak D, Abrey LE, Mikkelsen T, Jain R, Paleologos NA, Rn PL, Prados M, Goldin J, Wen PY, Cloughesy T. Apparent diffusion coefficient histogram analysis stratifies progression-free and overall survival in patients with recurrent GBM treated with bevacizumab: a multi-center study. J Neurooncol. e-Pub 3/18/2012. PMID: 22426926.
55. Koul D, Fu J, Shen R, LaFortune TA, Wang S, Tiao N, Kim YW, Liu JL, Ramnarian D, Yuan Y, Garcia-Echevrria C, Maira SM, Yung WK. Antitumor activity of NVP-BKM120- a selective pan class 1 PI3 Kinase inhibitor showed differential forms of cell death based on P53 status of glioma cells. Clin Cancer Res 18(1):184-95, 1/1/2012. e-Pub 11/7/2011. PMCID: PMC3785365.
56. Yung WK. A year of continued growth and success. Neuro Oncol 14(1):1-2, 1/2012. PMID: 22200986.
57. W. K Alfred Yung. A year of continued growth and success. Neuro-Oncology 14(1):1-2, 1/2012.
58. Reardon DA, Cloughesy T, Rich J, Alfred Yung WK, Yung L, DiLea C, Huang J, Dugan M, Mietlowski W, Maes A, Conrad C. Pharmacokinetic drug interaction between AEE788 and RAD001 causing thrombocytopenia in patients with glioblastoma. Cancer Chemother Pharmacol 69(1):281-7, 1/2012. e-Pub 10/9/2011. PMID: 21984222.
59. Gomez-Manzano C, Jiang H, Alonso M, Yung WK, Fueyo J. Gene therapy. Handb Clin Neurol 104:331-8, 2012. PMID: 22230451.
60. Yao J, Zhao Q, Yuan Y, Zhang L, Liu X, Yung WK, Weinstein JN. Identification of Common Prognostic Gene Expression Signatures with Biological Meanings from Microarray Gene Expression Datasets. PLoS One 7(9):e45894, 2012. e-Pub 9/21/2012. PMCID: PMC3448701.
61. Zhang N, Wei P, Gong A, Chiu WT, Lee HT, Colman H, Huang H, Xue J, Liu M, Wang Y, Sawaya R, Xie K, Yung WK, Medema RH, He X, Huang S. FoxM1 Promotes ß-Catenin Nuclear Localization and Controls Wnt Target-Gene Expression and Glioma Tumorigenesis. Cancer Cell 20(4):427-42, 10/18/2011. PMCID: PMC3199318.
62. Clarke JL, Ennis MM, Yung WK, Chang SM, Wen PY, Cloughesy TF, Deangelis LM, Robins HI, Lieberman FS, Fine HA, Abrey L, Gilbert MR, Mehta M, Kuhn JG, Aldape KD, Lamborn KR, Prados MD, North American Brain Tumor Consortium. Is surgery at progression a prognostic marker for improved 6-month progression-free survival or overall survival for patients with recurrent glioblastoma? Neuro Oncol 13(10):1118-24, 10/2011. e-Pub 8/2/2011. PMCID: PMC3177665.
63. Atkinson JM, Shelat AA, Carcaboso AM, Kranenburg TA, Arnold LA, Boulos N, Wright K, Johnson RA, Poppleton H, Mohankumar KM, Féau C, Phoenix T, Gibson P, Zhu L, Tong Y, Eden C, Ellison DW, Priebe W, Koul D, Yung WK, Gajjar A, Stewart CF, Guy RK, Gilbertson RJ. An integrated in vitro and in vivo high-throughput screen identifies treatment leads for ependymoma. Cancer Cell 20(3):384-99, 9/13/2011. PMCID: PMC3172881.
64. Siker ML, Wang M, Porter K, Nelson DF, Curran WJ, Michalski JM, Souhami L, Chakravarti A, Yung WK, Delrowe J, Coughlin CT, Mehta MP. Age as an independent prognostic factor in patients with glioblastoma: a radiation therapy oncology group and American College of Surgeons National Cancer Data Base comparison. J Neurooncol 104(1):351-6, 8/2011. e-Pub 1/9/2011. PMID: 21221714.
65. de Groot JF, Piao Y, Tran H, Gilbert M, Wu HK, Liu J, Bekele BN, Cloughesy T, Mehta M, Robins HI, Lassman A, DeAngelis L, Camphausen K, Chen A, Yung WK, Prados M, Wen PY, Heymach JV. Myeloid Biomarkers Associated with Glioblastoma Response to Anti-Vascular Endothelial Growth Factor Therapy with Aflibercept. Clin Cancer Res 17(14):4872-81, 7/15/2011. e-Pub 6/1/2011. PMCID: PMC3139700.
66. de Groot JF, Lamborn KR, Chang SM, Gilbert MR, Cloughesy TF, Aldape K, Yao J, Jackson EF, Lieberman F, Robins HI, Mehta MP, Lassman AB, Deangelis LM, Yung WK, Chen A, Prados MD, Wen PY. Phase II Study of Aflibercept in Recurrent Malignant Glioma: A North American Brain Tumor Consortium Study. J Clin Oncol 29(19):2689-95, 7/1/2011. e-Pub 5/23/2011. PMCID: PMC3139373.
67. Guan S, Shen R, Lafortune T, Tiao N, Houghton P, Yung WK, Koul D. Establishment and characterization of clinically relevant models of ependymoma: a true challenge for targeted therapy. Neuro Oncol 13(7):748-58, 7/2011. e-Pub 6/8/2011. PMCID: PMC3129270.
68. Cancer Genome Atlas Research Network. Integrated genomic analyses of ovarian carcinoma. Nature 474(7353):609-615, 6/30/2011. e-Pub 6/29/2011. PMCID: PMC3163504.
69. Wefel JS, Cloughesy T, Zazzali JL, Zheng M, Prados M, Wen PY, Mikkelsen T, Schiff D, Abrey LE, Yung WK, Paleologos N, Nicholas MK, Jensen R, Vredenburgh J, Das A, Friedman HS. Neurocognitive function in patients with recurrent glioblastoma treated with bevacizumab. Neuro Oncol 13(6):660-8, 6/2011. e-Pub 5/9/2011. PMCID: PMC3107095.
70. Wick W, Weller M, Weiler M, Batchelor T, Yung AW, Platten M. Pathway inhibition: emerging molecular targets for treating glioblastoma. Neuro Oncol 13(6):566-79, 6/2011. PMCID: PMC3107100.
71. Iwamoto FM, Lamborn KR, Kuhn JG, Wen PY, Yung WK, Gilbert MR, Chang SM, Lieberman FS, Prados MD, Fine HA. A phase I/II trial of the histone deacetylase inhibitor, romidepsin, for adults with recurrent malignant glioma: North American Brain Tumor Consortium Study 03-03. Neuro Oncol 13(5):509-16, 5/2011. e-Pub 3/3/2011. PMCID: PMC3093337.
72. Lawrence YR, Wang M, Dicker AP, Andrews D, Curran WJ, Michalski JM, Souhami L, Yung WK, Mehta M. Early toxicity predicts long-term survival in high-grade glioma. Br J Cancer 104(9):1365-71, 4/26/2011. e-Pub 4/12/2011. PMCID: PMC3101937.
73. Walbert T, Gilbert MR, Groves MD, Puduvalli VK, Yung WK, Conrad CA, Bobustuc GC, Colman H, Hsu SH, Bekele BN, Qiao W, Levin VA. Combination of 6-thioguanine, capecitabine, and celecoxib with temozolomide or lomustine for recurrent high-grade glioma. J Neurooncol 102(2):273-80, 4/2011. e-Pub 7/23/2010. PMID: 20652724.
74. Kim YW, Liu TJ, Koul D, Tiao N, Feroze AH, Wang J, Powis G, Yung WK. Identification of novel synergistic targets for rational drug combinations with PI3 kinase inhibitors using siRNA synthetic lethality screening against GBM. Neuro Oncol 13(4):367-75, 4/2011. PMCID: PMC3064700.
75. Fueyo J, Gomez-Manzano C, Yung WK. Advances in translational research in neuro-oncology. Arch Neurol 68(3):303-8, 3/2011. e-Pub 11/8/2010. PMCID: PMC3109723.
76. Gwak HS, Shingu T, Chumbalkar V, Hwang YH, DeJournett R, Latha K, Koul D, Alfred Yung WK, Powis G, Farrell NP, Bögler O. Combined action of the dinuclear platinum compound BBR3610 with the PI3-K inhibitor PX-866 in glioblastoma. Int J Cancer 128(4):787-96, 2/15/2011. e-Pub 4/2010. PMCID: PMC2990813.
77. Liu JL, Mao Z, Gallick GE, Yung WK. AMPK/TSC2/mTOR-signaling intermediates are not necessary for LKB1-mediated nuclear retention of PTEN tumor suppressor. Neuro Oncol 13(2):184-94, 2/2011. e-Pub 12/1/2010. PMCID: PMC3064623.
78. W. K. Alfred Yung. Reflections on a successful 2010. Neuro-Oncology 13(1):1-2, 1/2011.
79. Prados M, Cloughesy T, Samant M, Fang L, Wen PY, Mikkelsen T, Schiff D, Abrey LE, Yung WK, Paleologos N, Nicholas MK, Jensen R, Vredenburgh J, Das A, Friedman HS. Response as a predictor of survival in patients with recurrent glioblastoma treated with bevacizumab. Neuro Oncol 13(1):143-51, 1/2011. e-Pub 11/17/2010. PMCID: PMC3018914.
80. Gilbert MR, Gonzalez J, Hunter K, Hess K, Giglio P, Chang E, Puduvalli V, Groves MD, Colman H, Conrad C, Levin V, Woo S, Mahajan A, de Groot J, Yung WK. A phase I factorial design study of dose-dense temozolomide alone and in combination with thalidomide, isotretinoin, and/or celecoxib as postchemoradiation adjuvant therapy for newly diagnosed glioblastoma. Neuro Oncol 12(11):1167-72, 11/2010. e-Pub 8/20/2010. PMCID: PMC3098026.
81. Yung WK, Vredenburgh JJ, Cloughesy TF, Nghiemphu P, Klencke B, Gilbert MR, Reardon DA, Prados MD. Safety and efficacy of erlotinib in first-relapse glioblastoma: a phase II open-label study. Neuro Oncol 12(10):1061-70, 10/2010. e-Pub 7/2010. PMCID: PMC3018931.
82. Koul D, Shen R, Kim YW, Kondo Y, Lu Y, Bankson J, Ronen SM, Kirkpatrick DL, Powis G, Yung WK. Cellular and in vivo activity of a novel PI3K inhibitor, PX-866, against human glioblastoma. Neuro Oncol 12(6):559-69, 6/2010. e-Pub 2/2010. PMCID: PMC2940638.
83. Raizer JJ, Abrey LE, Lassman AB, Chang SM, Lamborn KR, Kuhn JG, Yung WK, Gilbert MR, Aldape KD, Wen PY, Fine HA, Mehta M, Deangelis LM, Lieberman F, Cloughesy TF, Robins HI, Dancey J, Prados MD, North American Brain Tumor Consortium. A phase I trial of erlotinib in patients with nonprogressive glioblastoma multiforme postradiation therapy, and recurrent malignant gliomas and meningiomas. Neuro Oncol 12(1):87-94, 1/2010. e-Pub 12/2009. PMCID: PMC2940559.
84. Raizer JJ, Abrey LE, Lassman AB, Chang SM, Lamborn KR, Kuhn JG, Yung WK, Gilbert MR, Aldape KA, Wen PY, Fine HA, Mehta M, Deangelis LM, Lieberman F, Cloughesy TF, Robins HI, Dancey J, Prados MD, North American Brain Tumor Consortium. A phase II trial of erlotinib in patients with recurrent malignant gliomas and nonprogressive glioblastoma multiforme postradiation therapy. Neuro Oncol 12(1):95-103, 1/2010. e-Pub 12/14/2009. PMCID: PMC2940554.
85. Norden AD, Raizer JJ, Abrey LE, Lamborn KR, Lassman AB, Chang SM, Yung WK, Gilbert MR, Fine HA, Mehta M, Deangelis LM, Cloughesy TF, Robins HI, Aldape K, Dancey J, Prados MD, Lieberman F, Wen PY. Phase II trials of erlotinib or gefitinib in patients with recurrent meningioma. J Neurooncol 96(2):211-7, 1/2010. e-Pub 6/2009. PMID: 19562255.
86. Vredenburgh JJ, Cloughesy T, Samant M, Prados M, Wen PY, Mikkelsen T, Schiff D, Abrey LE, Yung WK, Paleologos N, Nicholas MK, Jensen R, Das A, Friedman HS. Corticosteroid use in patients with glioblastoma at first or second relapse treated with bevacizumab in the BRAIN study. Oncologist 15(12):1329-34, 2010. e-Pub 12/8/2010. PMID: 21147867.
87. Zhou YH, Hess KR, Raj VR, Yu L, Liu L, Yung AW, Linskey ME. Establishment of prognostic models for astrocytic and oligodendroglial brain tumors with standardized quantification of marker gene expression and clinical variables. Biomark Insights 5:153-68, 2010. e-Pub 12/2010. PMCID: PMC3018892.
88. Friedman HS, Prados MD, Wen PY, Mikkelsen T, Schiff D, Abrey LE, Yung WK, Paleologos N, Nicholas MK, Jensen R, Vredenburgh J, Huang J, Zheng M, Cloughesy T. Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma. J Clin Oncol 27(28):4733-40, 10/2009. e-Pub 8/2009. PMID: 19720927.
89. Groves MD, Hess KR, Puduvalli VK, Colman H, Conrad CA, Gilbert MR, Weinberg J, Cristofanilli M, Yung WK, Liu TJ. Biomarkers of Disease: Cerebrospinal fluid Vascular Endothelial Growth factor (VEGF) and Stromal cell derived factor (SDF-1) levels in patients with neoplastic meningitis (NM) due to breast cancer, lung cancer and melanoma. J Neurooncol 94(2):229-34, 9/2009. e-Pub 3/7/2009. PMID: 19267183.
90. Liu TJ, Koul D, LaFortune T, Tiao N, Shen RJ, Maira SM, Garcia-Echevrria C, Yung WK. NVP-BEZ235, a novel dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor, elicits multifaceted antitumor activities in human gliomas. Mol Cancer Ther 8(8):2204-10, 8/2009. e-Pub 8/11/2009. PMCID: PMC2752877.
91. Groves MD, Puduvalli VK, Gilbert MR, Levin VA, Conrad CA, Liu VH, Hunter K, Meyers C, Hess KR, Alfred Yung WK. Two phase II trials of temozolomide with interferon-alpha2b (pegylated and non-pegylated) in patients with recurrent glioblastoma multiforme. Br J Cancer 101(4):615-20, 8/2009. PMCID: PMC2736828.
92. Wen PY, Yung WK, Lamborn KR, Norden AD, Cloughesy TF, Abrey LE, Fine HA, Chang SM, Robins HI, Fink K, Deangelis LM, Mehta M, Di Tomaso E, Drappatz J, Kesari S, Ligon KL, Aldape K, Jain RK, Stiles CD, Egorin MJ, Prados MD. Phase II study of imatinib mesylate (Gleevec(R)) for recurrent meningiomas (North American Brain Tumor Consortium Study 01-08). Neuro Oncol 11(6):853-60, 3/2009. e-Pub 3/2009. PMCID: PMC2802405.
93. Powis G, Ihle NT, Yung WK. Inhibiting PI-3-K for glioma therapy. Cell Cycle 8(3):335, 2/1/2009. e-Pub 2/1/2009. PMID: 19164951.
94. Gomez-Manzano C, Holash J, Fueyo J, Xu J, Conrad CA, Aldape KD, de Groot JF, Bekele BN, Yung WK. VEGF Trap induces antiglioma effect at different stages of disease. Neuro Oncol 10(6):940-5, 12/2008. e-Pub 8/2008. PMID: 18708344.
95. Cancer Genome Atlas Research Network [Yung WK]. Comprehensive genomic characterization defines human glioblastoma genes and core pathways. Nature 455(7216):1061-8, 10/2008. e-Pub 9/2008. PMCID: PMC2671642.
96. de Groot JF, Gilbert MR, Aldape K, Hess KR, Hanna TA, Ictech S, Groves MD, Conrad C, Colman H, Puduvalli VK, Levin V, Yung WK. Phase II study of carboplatin and erlotinib (Tarceva, OSI-774) in patients with recurrent glioblastoma. J Neurooncol 90(1):89-97, 10/2008. e-Pub 6/2008. PMID: 18581057.
97. de Groot JF, Yung WK. Bevacizumab and irinotecan in the treatment of recurrent malignant gliomas. Cancer J 14(5):279-85, Sep-Oct, 9/2008. PMID: 18836331.
98. Chang SM, Lamborn KR, Kuhn JG, Yung WK, Gilbert MR, Wen PY, Fine HA, Mehta MP, DeAngelis LM, Lieberman FS, Cloughesy TF, Robins HI, Abrey LE, Prados MD, North American Brain Tumor Consortium. Neuro-Oncology clinical trial design for targeted therapies -- Lessons learned from the North American Brain Tumor Consortium. Neuro Oncol 10(4):631-642, 8/2008. e-Pub 6/2008. PMCID: PMC2666238.
99. Knisely JP, Berkey B, Chakravarti A, Yung AW, Curran WJ, Jr, Robins HI, Movsas B, Brachman DG, Henderson RH, Mehta MP. A phase III study of conventional radiation therapy plus thalidomide versus conventional radiation therapy for multiple brain metastases (RTOG 0118). Int J Radiation Oncol Biol Phys 17((1)):79-86, 5/2008. e-Pub 11/2007.
100. Prados MD, Yung WKA, Wen PY, Junck L, Cloughesy T, Fink K, Chang S, Robins HI, Dancey J, Kuhn J.. Phase I trial of gefitinib and temozolomide in patients with malignant gliomas: A North American Brain Tumor Consortium Study. Cancer Chemother Pharmacol 61((6)):1059-1067, 5/2008. e-Pub 8/2007. PMID: 17694310.
101. Corn BW, Moughan J, Knisely JP, Fox SW, Chakravarti A, Yung WK, Curran WJ Jr, Robins HI, Brachman DG, Henderson RH, Mehta MP, Movsas B. Prospective evaluation of quality of life and neurocognitive effects in patients with multiple brain metastases receiving whole-brain radiotherapy with or without thalidomide on Radiation Therapy Oncology (RTOG) Trial 0118. Int J Radiat Oncol Biol Phys 71((1)):71-8, 5/2008. e-Pub 12/2007. PMID: 18164829.
102. Groves MD, Glantz MJ, Chamberlain MC, Baumgartner KE, Conrad CA, Hsu S, Wefel JS, Gilbert MR, Ictech S, Hunter KU, Forman AD, Puduvalli VK, Colman H, Hess KR, Yung WK. A multicenter Phase II trial of intrathecal topotecan in patients with meningeal malignancies. Neuro Oncol 10(2):208-215, 4/2008. e-Pub 3/2008. PMCID: PMC2613823.
103. Puduvalli VK, Giglio P, Groves MD, Hess KR, Gilbert MR, Mahankali S, Jackson EF, Levin VA, Conrad CA, Hsu SH, Colman H, de Groot JF, Ritterhouse MG, Ictech SE, Yung WK. Phase II trial of irinotecan and thalidomide in adults with recurrent glioblastoma multiforme. Neuro Oncol 10(2):216-222, 4/2008. e-Pub 2/2008. PMCID: PMC2613824.
104. Lamborn KR, Yung WK, Chang SM, Wen PY, Cloughesy TF, DeAngelis LM, Robins HI, Lieberman FS, Fine HA, Fink KL, Junck L, Abrey L, Gilbert MR, Mehta M, Kuhn JG, Aldape KD, Hibberts J, Peterson PM, Prados MD, North American Brain Tumor Consortium. Progression-free survival: An important end point in evaluating therapy for recurrent high-grade gliomas. Neuro Oncol 10(2):162-170, 4/2008. e-Pub 3/2008. PMCID: PMC2613818.
105. deGroot JF, Piao Y, Lu L, Fuller Gn, Yung WK. Knockdown of GluR1 expression by RNA interference inhigits glioma proliferation. J Neurooncol 88(2):121-33, 3/2008. e-Pub 3/2008. PMID: 18317690.
106. Freire P, Vilela M, Deus H, Kim YW, Koul D, Colman H, Aldape KD, Bogler O, Yung WK, Coombes K, Mills GB, Vasconcelos AT, Almeida JS. Exploratory analysis of the copy number alterations in glioblastoma multiforme. PLoS One 3(12):e4076, 2008. e-Pub 12/30/2008. PMCID: PMC2605252.
107. Alonso M, Gomez-Manzano C, Bekele BN, Yung WKA, Fueyo-Margareto J. Adenovirus-based strategies overcome temozolomide resistance by silencing the 06-methylguanine-DNA methyltransferase promotor. Cancer Res 67((24)):11499-504, 12/2007. PMID: 18089777.
108. Loghin M, Prados M, Wen P, Junck L, Lieberman F, Fine H, Fink K, Mehta M, Kuhn J, Lamborn K, Chang S, Cloughesy T, DeAngelis L, Robins HI, Aldape K, Yung, WKA. Phase I study of Temozolomide and Irinotecan for recurrent malignant gliomas in patients receiving enzyme-inducing antiepileptic drugs: A North American Brain Tumor Consortium study. Clin Cancer Res 13((23)):7133-7138, 12/2007. PMID: 18056194.
109. Scheurer ME, Etzel CJ, Liu M, El-Zein R, Airewele GE, Malmer B, Aldape KD, Weinberg JS, Yung WK, Bondy MI. Aggregation of cancer in first-degree relatives of patients with glioma. Cancer Epidemiol Biomarkers Prev 16((11)):2491-5, 11/2007. PMID: 18006942.
110. Jing R, Choi W, Khan A. Hess K, Gerner EW, Casero RA Jr, Yung WK, Hamilton SR, Zhang W. Activation of polyamine catabolism by N1, N11-diethylnorspermine leads to cell death in glioblastoma. Int J Oncol 31((2)):431-40, 8/2007. PMID: 17611701.
111. Alonso MM, Gomez-Manzano C, Jiang H, Bekele NB, Piao Y, Yung WK, Alemany R, Fueyo J. Combination of the oncolytic adenovirus ICOVIR-5 with chemotherapy provides enhanced anti-glioma effect in vivo. Cancer Gene Ther 14(8):756-61, 6/2007. e-Pub 6/2007. PMID: 17557108.
112. Olson MV, Johnson DG, Jiang H, Xu J, Alonso MM, Aldape KD, Fuller GN, BEkele BN, Yung WK, Gomez-Manzano C, Fueyo J. Transgenic E2F1 expression in the mouse brain induces a human-like bimodal pattern of tumors. Cancer Res 67((9)):4005-09, 5/2007. PMID: 17483310.
113. Groves MD, Puduvalli VK, Chang SM, Conrad CA, Gilbert MR, Tremont-Lukats IW, Liu TJ, Peterson P, Schiff D, Cloughesy TF, Wen PY, Greenberg H, Abrey LE, Deangelis LM, Hess KR, Lamborn KR, Prados MD, Yung WK. A North American brain tumor consortium (NABTC 99-04) phase II trial of temozolomide plus thalidomide for recurrent glioblastoma multiforme. J Neurooncol 81(3)(3):271-7, 2/2007. e-Pub 9/2006. PMID: 17031561.
114. Xia D, Srinivas H, Ahn YH, Sethi G, Sheng X, Yung WK, Xia Q, Chiao PJ, Kim H, Brown PH, Wistuba,, II, Aggarwal BB, Kurie JM. Mitogen-activated protein kinase kinase-4 promotes cell survival by decreasing PTEN expression through an NFkappaB-dependent pathway. J Biol Chem 282(6)(6):3507-19, 2/2007. e-Pub 12/2006. PMID: 17158870.
115. Xia Y, Wang J, Liu TJ, Yung WK, Hunter T, Lu Z. c-Jun downregulation by HDAC3-dependent transcriptional repression promotes osmotic stress-induced cell apoptosis. Mol Cell 25(2)(2):219-32, 1/2007. PMCID: PMC1829326.
116. Koul D, Shen R, Shishodia S, Takada Y, Bhat KP, Reddy SA, Aggarwal BB, Yung WK. PTEN down regulates AP-1 and targets c-fos in human glioma cells Via PI3-kinase/Akt pathway. Mol Cell Biochem 300(1-2)(1-2):77-87, 1/2007. e-Pub 1/2007. PMID: 17235455.
117. Liu JL, Mao Z, LaFortune TA, Alonso MM, Gallick GE, Fueyo J, Yung WK. Cell cycle-dependent nuclear export of phosphatase and tensin homologue tumor suppressor is regulated by the phosphoinositide-3-kinase signaling cascade. Cancer Res 67:(22):11054-63, 2007. PMID: 18006852.
118. Pelloski CE, Ballman KV, Furth AF, Zhang L, Lin E, Sulman EP, Bhat K, McDonald JM, Yung WK, Colman H, Woo SY, Heimberger AB, Suki D, Prado M, Chang SM, Barker FG 2nd, Buckner JC, James CD, Aldape K. Epidermal growth factor receptor variant III status defines clinically distinct subtypes of glioblastoma. J Clin Oncol 1:25(16)(16):2288-2294, 2007. PMID: 17538175.
119. Lustig RA, Sieferheld W, Berkey B, Yung AW, Scarantino C, Movsas B, Jones CU, Simpson JR, Fishbach J, Curran WJ Jr. Imaging response in malignant glioma, RTOG 90-06. Am J Clin Oncol 30(1):32-37, 2007.
120. Liu TJ, LaFortune T, Honda T, Ohmori O, Hatakeyama S, Meyer T, deGroot J, Yung WKA. Inhibition of both focal adhesion kinase and insulin-like growth factor-I receptor kinase suppresses glioma proliferation in vitro and in vivo. Mol Cancer Ther 6(4)(4):1357-67, 2007. PMID: 17431114.
121. Alonso MM, Fueyo J, Yung WK, Gomez-Manzano C. E2F1 and telomerase: Alliance on the dark side. Cell Cycle 5(9):930-35, 2006. e-Pub 5/2006.
122. Koul D, Shen R, Bergh S, Sheng X, Shishodia S, LaFortune T, Liu Y, deGroot J, Mills GB, Yung WK. Inhibition of Akt survival pathway by a small molecule inhibitor in human glioblastoma. Mol Cancer Ther 5(3)(3):637-44, 2006. PMID: 16546978.
123. Gomez-Manzano C, Lemoine MG, Hu M, He J, Mitlianga P, Liu TJ, Yung AW, Fueyo J, Groves MD. Adenovirally-mediated transfer of E2F-1 potentiates chemosensitivity of human glioma cells to temozolomide and BCNU. Int J Oncol 19:359-65, 8/2001. PMID: 11445852.
124. Mohanam S, Jasti SL, Kondraganti SR, Chandrasekar N, Lakka SS, Kin Y, Fuller GN, Yung AW, Kyritsis AP, Dinh DH, Olivero WC, Gujrati M, Ali-Osman F, Rao JS. Down-regulation of cathepsin B expression impairs the invasive and tumorigenic potential of human glioblastoma cells. Oncogene 20:3665-73, 6/2001. PMID: 11439329.
125. Im SA, Kim JS, Gomez-Manzano C, Fueyo J, Liu TJ, Cho MS, Seong CM, Lee SN, Hong YK, Yung WK. Inhibition of breast cancer growth in vivo by antiangiogenesis gene therapy with adenovirus-mediated antisense-VEGF. Br J Cancer 84(9)(9):1252-7, 5/2001. PMID: 11336478.
126. Koul D, Yao Y, Abbruzzese JL, Yung WK, Reddy SA. Tumor suppressor MMAC/PTEN inhibits cytokine-induced NFkappaB activation without interfering with the IkappaB degradation pathway. J Biol Chem 276(14)(14):11402-408, 4/2001. e-Pub 1/12/2001. PMID: 11278366.
127. Ke LD, Chen Z, Yung WK. A reliability test of standard-based quantitative PCR: exogenous vs endogenous standards. Mol Cell Probes 14(2)(2):127-35, 4/2000. PMID: 10799275.
128. Osoba D, Brada M, Yung WK, Prados M. Health-related quality of life in patients treated with temozolomide versus procarbazine for recurrent glioblastoma multiforme. J Clin Oncol 18(7)(7):1481-91, 4/2000. PMID: 10735896.
129. Meyers CA, Hess KR, Yung WK, Levin VA. Cognitive function as a predictor of survival in patients with recurrent malignant glioma. J Clin Oncol 18(3)(3):646-50, 2/2000. PMID: 10653880.
130. Fine HA, Figg WD, Jaeckle K, Wen PY, Kyritsis AP, Loeffler JS, Levin VA, Black PM, Kaplan R, Pluda JM, Yung WK. Phase II trial of the antiangiogenic agent thalidomide in patients with recurrent high-grade gliomas. J Clin Oncol 18(4):708-15, 2/2000. PMID: 10673511.
131. Fueyo J, Gomez-Manzano C, Alemany R, Lee PS, McDonnell TJ, Mitlianga P, Shi YX, Levin VA, Yung WK, Kyritsis AP. A mutant oncolytic adenovirus targeting the Rb pathway produces anti-glioma effect in vivo. Oncogene 19(1)(1):2-12, 1/2000. PMID: 10644974.
132. Chintala SK, Kyritsis AP, Mohan PM, Mohanam S, Sawaya R, Gokslan Z, Yung WK, Steck P, Uhm JH, Aggarwal BB, Rao JS. Altered actin cytoskeleton and inhibition of matrix metalloproteinase expression by vanadate and phenylarsine oxide, inhibitors of phosphotyrosine phosphatases: modulation of migration and invasion of human malignant glioma cells. Mol Carcinog 26(4):274-85, 12/1999. PMID: 10569804.
133. Yung WK. BUdR radiosensitization in anaplastic astrocytoma. Int J Radiat Oncol Biol Phys 45(5):1105-6, 12/1999. PMID: 10613300.
134. Lang FF, Yung WK, Sawaya R, Tofilon PJ. Adenovirus-mediated p53 gene therapy for human gliomas. Neurosurgery 45(5):1093-104, 11/1999. PMID: 10549925.
135. Alemany R, Gomez-Manzano C, Balague C, Yung WK, Curiel DT, Kyritsis AP, Fueyo J. Gene therapy for gliomas: molecular targets, adenoviral vectors, and oncolytic adenoviruses. Exp Cell Res 252(1):1-12, 10/1999. PMID: 10502394.
136. Hess KR, Wong ET, Jaeckle KA, Kyritsis AP, Levin VA, Prados MD, Yung WK. Response and progression in recurrent malignant glioma. Neuro-Oncol 1(4):282-8, 10/1999. PMID: 11550320.
137. Yung WK, Prados MD, Yaya-Tur R, Rosenfeld SS, Brada M, Friedman HS, Albright R, Olson J, Chang SM, O'Neill AM, Friedman AH, Bruner J, Yue N, Dugan M, Zaknoen S, Levin VA. Multicenter phase II trial of temozolomide in patients with anaplastic astrocytoma or anaplastic oligoastrocytoma at first relapse. Temodal Brain Tumor Group. J Clin Oncol 17(9):2762-71, 9/1999. PMID: 10561351.
138. Fuller GN, Rhee CH, Hess KR, Caskey LS, Wang R, Bruner JM, Yung WK, Zhang W. Reactivation of insulin-like growth factor binding protein 2 expression in glioblastoma multiforme: a revelation by parallel gene expression profiling. Cancer Res 59(17):4228-32, 9/1999. PMID: 10485462.
139. Groves MD, Maor MH, Meyers C, Kyritsis AP, Jaeckle KA, Yung WK, Sawaya RE, Hess K, Bruner JM, Peterson P, Levin VA. A phase II trial of high-dose bromodeoxyuridine with accelerated fractionation radiotherapy followed by procarbazine, lomustine, and vincristine for glioblastoma multiforme. Int J Radiat Oncol Biol Phys 45(1):127-35, 8/1999. PMID: 10477016.
140. Wong ET, Hess KR, Gleason MJ, Jaeckle KA, Kyritsis AP, Prados MD, Levin VA, Yung WK. Outcomes and prognostic factors in recurrent glioma patients enrolled onto phase II clinical trials. J Clin Oncol 17(8):2572-8, 8/1999. PMID: 10561324.
141. Davies MA, Koul D, Dhesi H, Berman R, McDonnell TJ, McConkey D, Yung WK, Steck PA. Regulation of Akt/PKB activity, cellular growth, and apoptosis in prostate carcinoma cells by MMAC/PTEN. Cancer Res 59(11):2551-6, 6/1999. PMID: 10363971.
142. Tang P, Jasser SA, Sung JC, Shi Y, Steck PA, Yung WK. Transforming growth factor-alpha antisense vectors can inhibit glioma cell growth. J Neurooncol 43(2):127-35, 6/1999. PMID: 10533724.
143. Sano T, Lin H, Chen X, Langford LA, Koul D, Bondy ML, Hess KR, Myers JN, Hong YK, Yung WK, Steck PA. Differential expression of MMAC/PTEN in glioblastoma multiforme: relationship to localization and prognosis. Cancer Res 59(8):1820-4, 4/1999. PMID: 10213484.
144. Fueyo J, Gomez-Manzano C, Yung WK, Kyritsis AP. Targeting in gene therapy for gliomas. Arch Neurol 56(4):445-8, 4/1999. PMID: 10199333.
145. Rhee CH, Ruan S, Chen S, Chenchik A, Levin VA, Yung AW, Fuller GN, Zhang W. Characterization of cellular pathways involved in glioblastoma response to the chemotherapeutic agent 1, 3-bis(2-chloroethyl)-1-nitrosourea (BCNU) by gene expression profiling. Oncol Rep 6:393-401, 3/1999. PMID: 10023010.
146. Im SA, Gomez-Manzano C, Fueyo J, Liu TJ, Ke LD, Kim JS, Lee HY, Steck PA, Kyritsis AP, Yung WK. Antiangiogenesis treatment for gliomas: transfer of antisense-vascular endothelial growth factor inhibits tumor growth in vivo. Cancer Res 59(4):895-900, 2/1999. PMID: 10029081.
147. Steck PA, Lin H, Langford LA, Jasser SA, Koul D, Yung WK, Pershouse MA. Functional and molecular analyses of 10q deletions in human gliomas. Genes Chromosomes Cancer 24(2):135-43, 2/1999. PMID: 9885980.
148. Gomez-Manzano Yung WKA. Gene Therapy for Gliomas. BioMedicina 2, 1999.
149. Gomez-Manzano C, Fueyo J, Alameda F, Kyritsis AP, Yung WK. Gene therapy for gliomas: p53 and E2F-1 proteins and the target of apoptosis. Int J Mol Med 3(1):81-5, 1999. PMID: 9864390.
150. Gomez-Manzano C, Fueyo J, Alameda F, Kyritsis AP, Yung WKA. Gene therapy for gliomas: p53 and E2f1 proteins and the target of apoptosis. Bioorganic & Medicinal Chemistry Letters 3:81-85, 1999.
151. Uhm Yung WK. Neurologic Complications of Cancer Therapy. Curr Treat Options Neurol 5(1):428-437, 1999.
152. Davies MA, Lu Y, Sano T, Fang X, Tang P, LaPushin R, Koul D, Bookstein R, Stokoe D, Yung WK, Mills GB, Steck PA. Adenoviral transgene expression of MMAC/PTEN in human glioma cells inhibits Akt activation and induces anoikis. Cancer Res 58(23):5285-90, 12/1998. PMID: 9850049.
153. Sigurdson AJ, Bondy ML, Hess KR, Toms SA, Kyritsis AP, Gu J, Wang LE, Wang X, Adatto P, Bruner JL, Yung WK, Levin VA, Wei Q. Gamma-ray mutagen sensitivity and survival in patients with glioma. Clin Cancer Res 4(12):3031-5, 12/1998. PMID: 9865917.
154. Fueyo J, Gomez-Manzano C, Yung WK, Kyritsis AP. The functional role of tumor suppressor genes in gliomas: clues for future therapeutic strategies. Neurology 51:1250-5, 11/1998. PMID: 9818841.
155. Ke LD, Adler-Storthz K, Clayman GL, Yung AW, Chen Z. Differential expression of epidermal growth factor receptor in human head and neck cancers. Head Neck 20:320-7, 7/1998. PMID: 9588705.
156. Lang FF, Yung WK, Raju U, Libunao F, Terry NH, Tofilon PJ. Enhancement of radiosensitivity of wild-type p53 human glioma cells by adenovirus-mediated delivery of the p53 gene. J Neurosurg 89(1):125-32, 7/1998. PMID: 9647183.
157. Ke LD, Fueyo J, Chen X, Steck PA, Shi YX, Im SA, Yung WK. A novel approach to glioma gene therapy: down-regulation of the vascular endothelial growth factor in glioma cells using ribozymes. Int J Oncol 12(6):1391-6, 6/1998. PMID: 9592205.
158. Fueyo J, Gomez-Manzano C, Yung WK, Liu TJ, Alemany R, McDonnell TJ, Shi X, Rao JS, Levin VA, Kyritsis AP. Overexpression of E2F-1 in glioma triggers apoptosis and suppresses tumor growth in vitro and in vivo. Nat Med 4:685-90, 6/1998. PMID: 9623977.
159. Fueyo J, Gomez-Manzano C, Yung WK, Liu TJ, Alemany R, Bruner JM, Chintala SK, Rao JS, Levin VA, Kyritsis AP. Suppression of human glioma growth by adenovirus-mediated Rb gene transfer. Neurology 50:1307-15, 5/1998. PMID: 9595979.
160. Hess KR, Wong ET, Yung WK. Assessing response to chemotherapy in malignant glioma: the role of steroids. Neurology 50(4):1197-1198, 4/1998. PMID: 9566439.
161. Ligon AH, Pershouse MA, Jasser S, Hong YK, Yung WK, Steck PA. Differentially expressed gene products in glioblastoma cells suppressed for tumorigenicity. J Neurovirol 4(2):217-26, 4/1998. PMID: 9584958.
162. Fueyo J, Gomez-Manzano C, Puduvalli VK, Martin-Duque P, Perez-Soler R, Levin VA, Yung WK, Kyritsis AP. Adenovirus-mediated p16 transfer to glioma cells induces G1 arrest and protects from paclitaxel and topotecan: implications for therapy. Int J Oncol 12(3):665-9, 3/1998. PMID: 9472109.
163. Wong ET, Jackson EF, Hess KR, Schomer DF, Hazle JD, Kyritsis AP, Jaeckle KA, Yung WK, Levin VA, Leeds NE. Correlation between dynamic MRI and outcome in patients with malignant gliomas. Neurology 50(3):777-81, 3/1998. PMID: 9521274.
164. Fueyo J, Gomez-Manzano C, Yung WKA, Liu TJ, Alemany R, Bruner J, Levin VA, Kyritsis AP. Adenovirus-mediated Rb gene transfer suppresses human glioma growth. Neurology 50(5):1307-15, 1998.
165. Huai L, Bondy ML, Langford LA, Hess KR, Delclos GL, Uw X, Chan W, Pershouse MA, Yung WKA, Steck PA. Allelic deletion analysis of mMAC/PTEN and DMBT1 loci in gliomas: Relationship to prognostic significance. Clin Ca Research 4(10):2447-2454, 1998.
166. Puduvalli VP, Yung WKA. New frontiers in the therapy of malignant gliomas: Trends in experimental medicine and therapeutics. Forum 8:261-69, 1998.
167. Fueyo, Gomez-Manzano C, Mitlianga P, Lagos G, Yung WKA, Kyritsis AP. p16/Rb/E2F-1 Pathway in Gliomas: from Function to Therapy. Biotech Lab International 3:22-23, 1998.
168. Teng DH, Hu R, Lin H, Davis T, Iliev D, Frye C, Swedlund B, Hansen KL, Vinson VL, Gumpper KL, Ellis L, El-Naggar A, Frazier M, Jasser S, Langford LA, Lee J, Mills GB, Pershouse MA, Pollack RE, Tornos C, Troncoso P, Yung WK, Fujii G, Berson A, Bookstein R, Bolen JB< Tavtigian SV, Steck PA. MMAC1/PTEN mutations in primary tumor specimens and tumor cell lines. Cancer Res 57(23):5221-5, 12/1997. PMID: 9393738.
169. Tang P, Steck PA, Yung WK. The autocrine loop of TGF-alpha/EGFR and brain tumors. J Neurooncol 35(3):303-14, 12/1997. PMID: 9440027.
170. Pershouse MA, Ligon AH, Pereira-Smith OM, Killary AM, Yung WK, Steck PA. Suppression of transformed phenotype and tumorigenicity after transfer of chromosome 4 into U251 human glioma cells. Genes Chromosomes Cancer 20(3):260-7, 11/1997. PMID: 9365833.
171. Chintala SK, Fueyo J, Gomez-Manzano C, Venkaiah B, Bjerkvig R, Yung WK, Sawaya R, Kyritsis AP, Rao JS. Adenovirus-mediated p16/CDKN2 gene transfer suppresses glioma invasion in vitro. Oncogene 15(17):2049-57, 10/1997. PMID: 9366522.
172. Osoba D, Aaronson NK, Muller M, Sneeuw K, Hsu MA, Yung WK, Brada M, Newlands E. Effect of neurological dysfunction on health-related quality of life in patients with high-grade glioma. J Neurooncol 34(3):263-78, 9/1997. PMID: 9258818.
173. Kaba SE, Kyritsis AP, Conrad C, Gleason MJ, Newman R, Levin VA, Yung WK. The treatment of recurrent cerebral gliomas with all-trans-retinoic acid (tretinoin). J Neurooncol 34(2):145-51, 9/1997. PMID: 9210061.
174. Gomez-Manzano C, Fueyo J, Kyritsis AP, McDonnell TJ, Steck PA, Levin VA, Yung WK. Characterization of p53 and p21 functional interactions in glioma cells en route to apoptosis. J Natl Cancer Inst 89(14):1036-44, 7/1997. PMID: 9230885.
175. Wei Q, Bondy ML, Mao L, Gaun Y, Cheng L, Cunningham J, Fan Y, Bruner JM, Yung WK, Levin VA, Kyritsis AP. Reduced expression of mismatch repair genes measured by multiplex reverse transcription-polymerase chain reaction in human gliomas. Cancer Res 57(9):1673-7, 5/1997. PMID: 9135006.
176. Sneeuw KC, Aaronson NK, Osoba D, Muller MJ, Hsu MA, Yung WK, Brada M, Newlands ES. The use of significant others as proxy raters of the quality of life of patients with brain cancer. Med Care 35(5):490-506, 5/1997. PMID: 9140337.
177. Steck PA, Pershouse MA, Jasser SA, Yung WK, Lin H, Ligon AH, Langford LA, Baumgard ML, Hattier T, Davis T, Frye C, Hu R, Swedlund B, Teng DH, Tavtigian SV. Identification of a candidate tumour suppressor gene, MMAC1, at chromosome 10q23.3 that is mutated in multiple advanced cancers. Nat Genet 15(4):356-62, 4/1997. PMID: 9090379.
178. Ligon AH, Pershouse MA, Jasser SA, Yung WK, Steck PA. Identification of a novel gene product, RIG, that is down-regulated in human glioblastoma. Oncogene 14(9):1075-81, 3/1997. PMID: 9070656.
179. Kaba SE, Kyritsis AP, Hess K, Yung WK, Mercier R, Dakhil S, Jaeckle KA, Levin VA. TPDC-FuHu chemotherapy for the treatment of recurrent metastatic brain tumors. J Clin Oncol 15(3):1063-70, 3/1997. PMID: 9060546.
180. Pershouse MA, El-Naggar AK, Hurr K, Lin H, Yung WK, Steck PA. Deletion mapping of chromosome 4 in head and neck squamous cell carcinoma. Oncogene 14(3):369-73, 1/1997. PMID: 9018123.
181. Yung W. A Phase II Radiation Therapy Oncology Group study (RTOG 91-13) in patients with recurrent malignant astrocytoma. J of Neuro-Oncology 34(2):193-200, 1997.
182. Phuphanich S, Scott C, Fischbach AJ, Langer C, Yung WKA. All trans-retinoic acid A phase II Radiation Therapy Oncology Grop Study (RTOG 91-13) in patients with recurrent malignant astrocytoma. Journal of Neuro-Oncology 34(92):193-200, 1997.
183. Fueyo, Gomez-Manzano C, Bruner JM, Saito Y, Zhang B, Zhang W, Levin VA, Yung WKA, Kyritsis AP. Hypomethylation of the CpG island of p16/CDKN2 correlates with gene inactivation in gliomas. Oncogene 13(8):1615-1619, 1997.
184. Kaba SE, DeMonte F, Bruner JM, Kyritsis AP, Jaeckle KA, Levin V, Yung WKA. The treatment of recurrent unresectable and malignant meningiomas with interferon-alpha-2b. Neurosurgery 40(2):271-75, 1997.
185. Chin LS, Yung WKA, Raffel C. Two primitive neuroectodermal tumor cell lines require an activated insulin-like growth factor I receptor for growth in vitro. Neurosurgery 39(6):1183-90, 1997.
186. Yung WK, Kyritsis AP, Gleason MJ, Levin VA. Treatment of recurrent malignant gliomas with high-dose 13-cis-retinoic acid. Clin Cancer Res 2(12):1931-5, 12/1996. PMID: 9816151.
187. Kyritsis AP, Yung WK, Jaeckle KA, Bruner J, Gleason MJ, Ictech SE, Flowers A, Levin VA. Combination of 6-thioguanine, procarbazine, lomustine, and hydroxyurea for patients with recurrent malignant gliomas. Neurosurgery 39(5):921-6, 11/1996. PMID: 8905746.
188. Kaba SE, Langford LA, Yung WK, Kyritsis AP. Resolution of recurrent malignant ganglioglioma after treatment with cis-retinoic acid. J Neurooncol 30(1):55-60, 10/1996. PMID: 8865003.
189. Rao JS, Sawaya R, Gokaslan ZL, Yung WK, Goldstein GW, Laterra J. Modulation of serine proteinases and metalloproteinases during morphogenic glial-endothelial interactions. J Neurochem 66(4):1657-64, 4/1996. PMID: 8627323.
190. Gomez-Manzano C, Fueyo J, Kyritsis AP, Steck PA, Roth JA, McDonnell TJ, Steck KD, Levin VA, Yung WK. Adenovirus-mediated transfer of the p53 gene produces rapid and generalized death of human glioma cells via apoptosis. Cancer Res 56(4):694-9, 2/1996. PMID: 8630997.
191. Osoba D, Aaronson NK, Muller M, Sneeuw K, Hsu MA, Yung WK, Brada M, Newlands E. The development and psychometric validation of a brain cancer quality-of-life questionnaire for use in combination with general cancer-specific questionnaires. Qual Life Res 5(1):139-50, 2/1996. PMID: 8901377.
192. Fueyo J, Gomez-Manzano C, Yung WK, Clayman GL, Liu TJ, Bruner J, Levin VA, Kyritsis AP. Adenovirus-mediated p16/CDKN2 gene transfer induces growth arrest and modifies the transformed phenotype of glioma cells. Oncogene 12(1):103-10, 1996.
193. Fueyo J, Gomez-Manzano C, Yung WK, Zhang W, Lee PS, Majumder S, Perhouse M, Levin VA, Kyritsis AP. A frequent polymorphism in exon 1 of the p16/CDKN2 gene. Mol Cell Probes 9(6):465-6, 12/1995. PMID: 8808318.
194. Kyritsis AP, Bondy ML, Hess KR, Cunningham JE, Zhu D, Amos CJ, Yung WK, Levin VA, Bruner JM. Prognostic significance of p53 immunoreactivity in patients with glioma. Clin Cancer Res 1(12):1617-22, 12/1995. PMID: 9815964.
195. Levin VA, Maor MH, Thall PF, Yung WK, Bruner J, Sawaya R, Kyritsis AP, Leeds N, Woo S, Rodriguez L, et al. Phase II study of accelerated fractionation radiation therapy with carboplatin followed by vincristine chemotherapy for the treatment of glioblastoma multiforme. Int J Radiat Oncol Biol Phys 33(2):357-64, 9/1995. PMID: 7673023.
196. Korkmaz M, Kim EE, Wong FC, Podoloff DA, Haynie TP, Yung A. In-111 DTPA Ommayagrams in leptomeningeal carcinomatosis. Clin Nucl Med 20(7):610-2, 7/1995. PMID: 7554663.
197. Van Tassel P, Bruner JM, Maor MH, Leeds NE, Gleason MJ, Yung WK, Levin VA. MR of toxic effects of accelerated fractionation radiation therapy and carboplatin chemotherapy for malignant gliomas. AJNR Am J Neuroradiol 16(4):715-26, 4/1995. PMID: 7611028.
198. Steck PA, Ligon AH, Cheong P, Yung WK, Pershouse MA. Two tumor suppressive loci on chromosome 10 involved in human glioblastomas. Genes Chromosomes Cancer 12(4):255-61, 4/1995. PMID: 7539279.
199. Yung WK. New approaches to molecular therapy of brain tumors. Curr Opin Neurol 7(6):501-5, 12/1994. PMID: 7866580.
200. Yung WK. New approaches in brain tumor therapy using gene transfer and antisense oligonucleotides. Curr Opin Oncol 6(3):235-9, 5/1994. PMID: 8080851.
201. Pershouse MA, Stubblefield E, Hadi A, Killary AM, Yung WK, Steck PA. Analysis of the functional role of chromosome 10 loss in human glioblastomas. Cancer Res 53(20):5043-50, 10/1993. PMID: 8104691.
202. Janus TJ, Kim EE, Tilbury R, Bruner JM, Yung WK. Use of [18F]fluorodeoxyglucose positron emission tomography in patients with primary malignant brain tumors. Ann Neurol 33(5):540-8, 5/1993. PMID: 8498831.
203. Kyritsis AP, Levin VA, Yung WK, Leeds NE. Imaging patterns of multifocal gliomas. Eur J Radiol 16(3):163-70, 4/1993. PMID: 8389708.
204. Meyers CA, Yung WK. Delayed neurotoxicity of intraventricular interleukin-2: a case report. J Neurooncol 15(3):265-7, 3/1993. PMID: 8360712.
205. Kyritsis AP, Yung WK, Bruner J, Gleason MJ, Levin VA. The treatment of anaplastic oligodendrogliomas and mixed gliomas. Neurosurgery 32(3):365-70; discussion 371, 3/1993. PMID: 8455760.
206. Steck PA, Bruner J, Pershouse MA, Hadi A, Conrad CA, Yung WKA, Saya H. Molecular, genetic, and biologic aspects of primary brain tumors. The Cancer Bulletin 45:296-302, 1993.
207. Levin VA, Prados MD, Yung WK, Gleason MJ, Ictech S, Malec M. Treatment of recurrent gliomas with eflornithine. J Natl Cancer Inst 84(18):1432-7, 9/1992. PMID: 1380989.
208. Kyritsis AP, Yung WK, Leeds NE, Bruner J, Gleason MJ, Levin VA. Multifocal cerebral gliomas associated with secondary malignancies. Lancet 339(8803):1229-30, 5/1992. PMID: 1349958.
209. Kim EE, Chung SK, Haynie TP, Kim CG, Cho BJ, Podoloff DA, Tilbury RS, Yang DJ, Yung WK, Moser RP, Jr, et al. Differentiation of residual or recurrent tumors from post-treatment changes with F-18 FDG PET. Radiographics 12(2):269-79, 3/1992. PMID: 1561416.
210. Yung WK, Janus TJ, Maor M, Feun LG. Adjuvant chemotherapy with carmustine and cisplatin for patients with malignant gliomas. J Neurooncol 12:131-5, 2/1992. PMID: 1560258.
211. Yung WK, Prados M, Levin VA, Fetell MR, Bennett J, Mahaley MS, Salcman M, Etcubanas E. Intravenous recombinant interferon beta in patients with recurrent malignant gliomas: a phase I/II study. J Clin Oncol 9(11):1945-9, 11/1991. PMID: 1658242.
212. Yung WK, Mechtler L, Gleason MJ. Intravenous carboplatin for recurrent malignant glioma: a phase II study. J Clin Oncol 9(5):860-4, 5/1991. PMID: 1849986.
213. Garden AS, Maor MH, Yung WK, Bruner JM, Woo SY, Moser RP, Lee YY. Outcome and patterns of failure following limited-volume irradiation for malignant astrocytomas. Radiother Oncol 20(2):99-110, 2/1991. PMID: 1851573.
214. Feun, Savaraj N, Lee YY, Landy H, Martinez-Prieto J, Charnsangavej C, Post JD, Lee KF, Wallace S, Bowen B, Kochan P, Yung WKA. A pilot clinical and pharmacokinetic study of intracarotid cisplatin and bleomycin. Selective Cancer Therapeutics 7:29-36, 1991.
215. Newton LK, Yung WK, Pettigrew LC, Steck PA. Growth regulatory activities of endothelial extracellular matrix: mediation by transforming growth factor-beta. Exp Cell Res 190(1):127-32, 9/1990. PMID: 2387324.
216. Yung WK. Chemotherapy for malignant brain tumors. Curr Opin Oncol 2(4):673-8, 8/1990. PMID: 2095876.
217. Yung WK, Castellanos AM, Van Tassel P, Moser RP, Marcus SG. A pilot study of recombinant interferon beta (IFN-beta ser) in patients with recurrent glioma. J Neurooncol 9(1):29-34, 1990. PMID: 2082958.
218. Yung WK, Zhang X, Steck PA, Hung MC. Differential amplification of the TGF-alpha gene in human gliomas. Cancer Commun 2(6):201-5, 1990. PMID: 2165797.
219. Rosenblum MG, Yung WK, Kelleher PJ, Ruzicka F, Steck PA, Borden EC. Growth inhibitory effects of interferon-beta but not interferon-alpha on human glioma cells: correlation of receptor binding, 2',5'-oligoadenylate synthetase and protein kinase activity. J Interferon Res 10(2):141-51, 1990. PMID: 2140395.
220. Steck PA, Hadi A, Lotan R, Yung WK. Inhibition of epidermal growth factor receptor activity by retinoic acid in glioma cells. J Cell Biochem 42(1):83-94, 1990. PMID: 2307713.
221. Steck PA, Moser RP, Bruner JM, Liang L, Freidman AN, Hwang TL, Yung WK. Altered expression and distribution of heparan sulfate proteoglycans in human gliomas. Cancer Res 49(8):2096-103, 1989. PMID: 2522816.
222. Yung WK. In vitro chemosensitivity testing and its clinical application in human gliomas. Neurosurg Rev 12(3):197-203, 1989. PMID: 2682352.
223. Yung WK, Harris MI, Bruner JM, Feun LG. Intravenous BCNU and AZQ in patients with recurrent malignant gliomas. J Neurooncol 7(3):237-40, 1989. PMID: 2795118.
224. Yung WK, Lotan R, Lee P, Lotan D, Steck PA. Modulation of growth and epidermal growth factor receptor activity by retinoic acid in human glioma cells. Cancer Res 49(4):1014-9, 1989. PMID: 2912547.
225. Maria BL, Steck PA, Yung WK, Milici A, Bruner JM, Pathak S, Becker FF. The modulation of astrocytic differentiation in cells derived from a medulloblastoma surgical specimen. J Neurooncol 7(4):329-38, 1989. PMID: 2555453.
226. Frappaz D, Singletary SE, Spitzer G, Yung A. Enhancement of growth of primary metastatic fresh human tumors of the nervous system by epidermal growth factor in serum-free short term culture. Neurosurgery 23:355-9, 9/1988. PMID: 3265764.
227. McLaughlin P, Velasquez WS, Redman JR, Yung WK, Hagemeister FB, Rodriguez MA, Cabanillas F. Chemotherapy with dexamethasone, high-dose cytarabine, and cisplatin for parenchymal brain lymphoma. J Natl Cancer Inst 80(17):1408-12, 1988. PMID: 3172268.
228. Steck PA, Lee P, Hung MC, Yung WK. Expression of an altered epidermal growth factor receptor by human glioblastoma cells. Cancer Res 48(19):5433-9, 1988. PMID: 3416300.
229. Iwata K, Yung WK, Fields WS. In vitro effects of ACNU, BCNU, CDDP, and bleomycin on human glioma cells. Neurol Med Chir (Tokyo) 28(10):965-9, 1988. PMID: 2462685.
230. Castellanos AM, Glass JP, Yung WK. Regional nerve injury after intra-arterial chemotherapy. Neurology 37(5):834-7, 5/1987. PMID: 3033546.
231. Steck PA, Cheong PH, Nakajima M, Yung WK, Moser RP, Nicolson GL. Altered expression of glycosaminoglycans in metastatic 13762NF rat mamma adenocarcinoma cells. Biochemistry 26(4):1020-8, 2/1987. PMID: 3567153.
232. Yung WK, Steck PA, Kelleher PJ, Moser RP, Rosenblum MG. Growth inhibitory effect of recombinant alpha and beta interferon on human glioma cells. J Neurooncol 5(4):323-30, 1987. PMID: 2964515.
233. Feun LG, Lee YY, Yung WK, Savaraj N, Wallace S. Intracarotid VP-16 in malignant brain tumors. J Neurooncol 4(4):397-401, 1987. PMID: 3572470.
234. Hromas RA, Yung WK. Anguidine potentiates cis-platinum in human brain tumor cells. J Neurooncol 3(4):343-8, 1986. PMID: 3958780.
235. Fainstein V, Leavens M, Moser C, Bray R, Obbens E, Yung WK, Glass P, Mansell PW. Brain and meningeal biopsy in patients with acquired immunodeficiency syndrome. Tex Med 82(1):40-5, 1986. PMID: 3003948.
236. Steck PA, Gallick GE, Maxwell SA, Kloetzer WS, Arlinghaus RB, Moser RP, Gutterman JU, Yung WK. Expression of epidermal growth factor receptor and associated glycoprotein on cultured human brain tumor cells. J Cell Biochem 32(1):1-10, 1986. PMID: 3533968.
237. Hwang TL, Yung WK, Lee YY, Borit A, Fields WS. High dose Ara-C related leukoencephalopathy. J Neurooncol 3(4):335-9, 1986. PMID: 3457103.
238. Feun LG, Lee YY, Yung WK, Charnsangavej C, Savaraj N, Tang RA, Wallace S. Phase II trial of intracarotid BCNU and cisplatin in primary malignant brain tumors. Cancer Drug Deliv 3(2):147-56, 1986. PMID: 3708537.
239. Hwang TL, Yung WK, Estey EH, Fields WS. Central nervous system toxicity with high-dose Ara-C. Neurology 35(10):1475-9, 10/1985. PMID: 4033929.
240. Feun LG, Yung WK, Stewart DJ, Savaraj N, Bodey GP. Phase II trial of mitogauzone in malignant primary brain tumors. Cancer Treat Rep 69(3):329-30, 3/1985. PMID: 3978660.
241. Yung WK, Luna M, Borit A. Vimentin and glial fibrillary acidic protein in human brain tumors. J Neurooncol 3(1):35-8, 1985. PMID: 3889231.
242. Feun LG, Wallace S, Stewart DJ, Chuang VP, Yung WK, Leavens ME, Burgess MA, Savaraj N, Benjamin RS, Young SE,Tang RA, Handel S, Mavligit G, Fields WS.. Intracarotid infusion of cis-diamminedichloroplatinum in the treatment of recurrent malignant brain tumors. Cancer 54(5):794-9, 9/1984. PMID: 6331626.
243. Feun LG, Yung WK, Leavens ME, Burgess MA, Obbens EA, Bedikian AY, Savaraj N, Stewart DJ, Benjamin RS, Fields WS, et al. A phase II trial of 2,5,-diaziridinyl 3,6-bis (carboethoxy amino) 1,4-benzoquinone (AZQ, NSC 182986) in recurrent primary brain tumors. J Neurooncol 2(1):13-7, 1984. PMID: 6088722.
244. Feun LG, Wallace S, Yung WK, Lee YY, Leavens ME, Moser R, Savaraj N, Burgess MA, Plager C, Benjamin RS, tang RA, Mavligit GM, Fields WS.. Phase-I trial of intracarotid BCNU and cisplatin in patients with malignant intracerebral tumors. Cancer Drug Deliv 1(3):239-45, 1984. PMID: 6544123.
245. Wang E, Cairncross JG, Yung WK, Garber EA, Liem RK. An intermediate filament-associated protein, p50, recognized by monoclonal antibodies. J Cell Biol 97:1507-14, 11/1983. PMID: 6355121.
246. Feun LG, Stewart DJ, Maor M, Leavens M, Savaraj N, Burgess MA, Yung WK, Benjamin RS. A pilot study of cis-diamminedichloroplatinum and radiation therapy in patients with high grade astrocytomas. J Neurooncol 1(2):109-13, 1983. PMID: 6088710.
247. Yung WK, Tepper SJ, Young DF. Diffuse bone marrow metastasis by glioblastoma: premortem diagnosis by peroxidase-antiperoxidase staining for glial fibrillary acidic protein. Ann Neurol 14(5):581-5, 1983. PMID: 6316836.
248. Yung WK, Shapiro JR, Shapiro WR. Heterogeneous chemosensitivities of subpopulations of human glioma cells in culture. Cancer Res 42(3):992-8, 1982. PMID: 7199383.
249. Shapiro WR, Yung WA, Basler GA, Shapiro JR. Heterogeneous response to chemotherapy of human gliomas grown in nude mice and as clones in vitro. Cancer Treat Rep 65 Suppl 2:55-9, 1981. PMID: 7346147.
250. Shapiro JR, Yung WK, Shapiro WR. Isolation, karyotype, and clonal growth of heterogeneous subpopulations of human malignant gliomas. Cancer Res 41(6):2349-59, 1981. PMID: 7016313.
251. Yung WA, Horten BC, Shapiro WR. Meningeal gliomatosis: a review of 12 cases. Ann Neurol 8:605-8, 12/1980. PMID: 6260012.
252. Yung WK, Steward W, Marks JE, Griem ML, Mullan JF. Glioblastoma multiforme: treatment with radiation and triiodothyronine. Int J Radiat Oncol Biol Phys 1(7):645-50, 7/1976. PMID: 185171.
253. Yung WK, Blank NK, Vick NA. Glioblastoma. Induction of a reproducible autochonous tumor in rats with murine sarcoma virus. Neurology 26(1):76-83, 1976. PMID: 174026.
254. Maruyama Y, Gedgaudes RK, Lee TC, Yung WK. DNA synthesis in fast- and slow-growing C57BL ascites tumors. Cancer Res 34(10):2580-4, 10/1974. PMID: 4412879.

Invited Articles

1. Conrad CA, Milosavljevic VP, Yung WK. Advances in chemotherapy for brain tumors. Neurol Clin 13(4):795-812, 11/1995. PMID: 8583997.
2. Yung WK. Molecular biology, genetics, and central nervous system neoplasms. Commentary. Curr Opin Neurol 7(6):475-76, 12/1994. PMID: 7866577.
3. Yung WKA. Neoplasms. Section Editor. Current Opinion in Neurology 7:476-505, 1994.
4. Yung WKA. Chemotherapy for malignant brain tumors. Cancer Bulletin 45:357-61, 1993.
5. Steck PA, Bruner JM, Pershouse MA, Hadi A, Conrad CA, Yung WKA, and Saya H. Molecular genetic and biological aspects of primary brain tumors. Cancer Bulletin, 1993.
6. Kim EE, Wong FCL, Wong WHG, Tilbury R, Podoloff DA, Haynie TP, Leeds NE, Yung WKA, Sawaya R. Positron-emission tomography in clinical neuro-oncology. Neuroimaging Clinics of North America 3(4):1-8, 1993.
7. Moser RP, Johnson ML, Yung WKA. Metastatic brain cancer in patients with no known primary site. Cancer Bulletin 41:173-78, 1989.
8. Yung WKA. Pitfalls and controversies in diagnosis and treatment (consultant). J Medical Consultation, 1988.
9. Steck PA, Gallick GE, Hwant TL, Yung WKA. Altered expression of cell surface glycoproteins as markers for brain tumors. Cancer Bulletin 38:10-14, 1986.
10. Yung WKA, Moser RP. Heterogeneity and chemosensitivity of cellular DNA in human gliomas. Cancer Bulletin 39:7-10, 1986.
11. Martinez Prieto JN, Yung WKA, Feun LG, and Lee YY. Toxicity of intracarotid chemotherapy for patients with malignant brain tumors. Cancer Bulletin 38:49-52, 1986.
12. Yung WK, Hwang TL, Martinez-Prieto J, Lee YY, Feun LG. Neurotoxicity of high-dose Ara-C and intracarotid chemotherapy. Prog Exp Tumor Res 29:183-9, 1985. PMID: 4070631.
13. Feun LG, Lee YY, Wallace S, Charn C, Savaraj N, Carrasco CH, Gianturco C, and Yung WKA. New Drugs and New Delivery Techniques. Progress in Experimental Tumor Research 29:131-39, 1985.

Editorials

1. Chang S, Yung WK. New neuro-oncology practice journal to launch in 2014. Neuro Oncol 15(10):1277, 10/2013. PMCID: PMC3779050.
2. Yung WK. Higher impact, wider influence. Neuro Oncol 15(9):1113, 9/2013. PMCID: PMC3748927.
3. Yung WK. Year brings higher impact factor, more submissions for Neuro-Oncology. Neuro Oncol 15(1):1-3, 1/2013. PMCID: PMC3534432.
4. Yung WK. The value of cell line validation. Neuro Oncol 14(6):675, 6/2012. PMCID: PMC3367857.
5. Yung WK. New impact factor number reflects sustained and enhanced growth. Neuro Oncol 13(9):925, 9/2011. PMCID: PMC3158021.
6. Yung WK. Reflections on a successful 2010. Neuro Oncol 13(1):1-2, 1/2011. PMID: 21193689.
7. Yung WK. The problem with cell phones..or maybe not. Neuro Oncol 12(11):1087, 11/2010. PMID: 20966155.
8. Yung WK. Impact Factor number reflects sustained high quality. Neuro Oncol 12(9):893, 9/2010. PMCID: PMC2940697.
9. Yung WK. Journal to shift practice on obtaining conflict of interest declarations. Neuro Oncol 12(7):619-20, 7/2010. PMID: 22156772.
10. Yung WK. Quality of Life: A Fertile Field for Inquiry. Neuro Oncol 11(3):241, 6/2009. e-Pub 4/29/2009. PMCID: PMC2718967.
11. Yung WK. To publish or not to publish.. Neuro Oncol 11(1):1, 2/2009. e-Pub 12/2008. PMID: 19106331.
12. Yung WK. Moving toward the next steps in angiogenesis therapy? Neuro Oncol 10(6):939, 12/2008. e-Pub 11/2008. PMID: 18981258.
13. Yung, WKA. Impact factor grows, thanks to hard-working reviewers. Neuro-Oncology 10:539, 8/2008.
14. Yung WKA. Value of meetings is far from abstract. Neuro-Oncology 10:235, 6/2008.
15. Yung WKA. "Review"-ing our new opportunities for "Rapid Report"-ing. Neuro-Oncology 10:111, 4/2008. PMID: 18326687.
16. Yung WK. Carrying Neuro-Oncology to a world that needs knowledge. Neuro Oncol 10(1):1, 2/2008. e-Pub 1/9/2008. PMCID: PMC2600829.
17. Yung WK, James CD. Mapping the future of Neuro-Oncology. Neuro Oncol 9(1)(1):1-2, 1/2007. e-Pub 11/2006. PMCID: PMC1828102.
18. Yung WK, James CD. Focusing in, broadening our reach. Neuro-Oncology 9(2):81, 2007. e-Pub 3/2007.
19. Bigner DD, Yung WKA, James CD, Cohen SA. Neuro-Oncology impact factor for 2005. Neuro-Oncology 8:289, 2006.

Abstracts

1. Liu AL, Yung WK, Yeung HN, Lai SF, Lam MT, Lai FK, Lo TK, Lau WL, Leung WC. Factors influencing the mode of delivery and associated pregnancy outcomes for twins: a retrospective cohort study in a public hospital. Hong Kong Med J 18(2):99-107, 4/2012. PMID: 22477732.
2. Fu J, Koul D, Yao J, Wang S, Gumin J, Shen R, Vaillant B, Colman H, Lang FF, Aldape K, Yung WK. Molecular and lineage analysis of Glioblastoma Stem Cells identifieds clinically relevant models of glioblastoma, 2011.
3. Colman H, Conrad C A, Sai K, Wang S, Popoff S, Aldape K, Lang F, Fokt I, Madden T L, Yung W K, Preibe W. WP1193 Inhibits JAK2/STAT3 Pathway, blocks self-renewal and induces apoptosis in glioblastoma cancer stem cells Proceeding of the American Association of Cancer Research, Denver, CO 4/09 (#4800), 2009.
4. Cloughesy TF, Prados MD, Wen PY, Mikkelsen T, Abrey LE, Schiff D, Yung WK, Maoxia Z, Dimery I, Friedman HS. A phase II, randomized, non-comparative clinical trial of the effect of bevacizumab (BV) alone or in combination with irinotecan (CPT) on 6-month progression free survival (PFS6) in recurrent, treatment-refractory glioblastoma (GBM). J Clinical Oncol Abstract #2010b:226 (#2010b), 6/2008.
5. Colman H, Sai K, Wang S, Popoff S, Aldape KD, Lang FF, Conrad CA, Madden T, Yung A, Priebe W. Effect of small molecule inhibitor of the JAK2/STAT3 pathway on self-renewal of glioblastoma stem cells. Proceedings of the American Society for Clinical Oncology Abstract #2003 (#2003), 6/2008.
6. deGroot JF, Wen PY, Lamborn K, Chang S, Cloughesy TF, Chen AP, DeAngelis LM, Mehta MP, Gilbert MR, Yung WK, Prados MD. Phase II single arm trial of aflibercept in patients with recurrent temozolomide-resistant glioblastoma: NABTC 0601. Proceedings of the American Society for Clinical Oncology Abstract #2020 (#2020), 6/2008.
7. White EJ, Jiang H, Alonso M, Piao Y, Xu J, Conrad C, Yung WKA. Atg5 is required for adenovirus-induced autophagy in cancer cells. Proceedings of the 99th American Association of Cancer Research Abstract #3357 (#3357), 4/2008.
8. Koul D, Shen R, Edge J, Henry V, Webb D, Bankson J, Ronen SM, Powis G, Kirkpatrick DL, Yung AWK. Cellular and in vivo activity of a new PI3K inhibitor - PX866 for treatment of human glioblastoma. Proceedings of the 99th American Association of Cancer Research Abstract #3731 (#3731), 4/2008.
9. Jiang H, Xu J, Lang F, Colman H, Gomez-Manzano C, Bogler O, Latha K, Yung WKA,Fueyo J. Delta-24-RD induces autophagy in brain tumor stem cells and prolongs survival in glioma-bearing mice. Proceedings of the 99th American Association of Cancer Research Abstract #3304 (#3304), 4/2008.
10. Kim YW, Tiao N, Lafortune T, Liu TJ, Powis G, Yung WKA, Koul D. Identification of novel synergistic targets RACK-1 and galectin-1 for rational drug combinations with PI3 Kinase inhibitors using siRNA synthetic lethality screening. Proceedings of the 99th American Association of Cancer Research Abstract #2761 (#2761), 4/2008.
11. Liu JL, Mao Z, LaFortune TA, Liu TJ, Garnett J, Yung WKA. Nuclear PTEN-mediated autophagy is independent of mTOR inhibition in U251MG cells. Proceedings of the 99th American Association of Cancer Research Abstract #3367 (#3367), 4/2008.
12. Alonso MM, Gomez-Manzano C, Jiang H, Martin V, Liu D, Xu J, Yung WKA, Gilbert M, Fueyo J. Role of the silencing of the MGMT promoter in the therapeutic synergy between Delta-24-RGD and temozolomide. Proceedings of the 99th American Association of Cancer Research Abstract #1364 (#1364), 4/2008.
13. Liu JL, Mao Z, Garnett J, Bogler O, Yung WKA. Subcellular localization of PTEN is regulated by LKB1 with or without the AMPK/TSC2/mTOR signaling intermediates. Proceedings of the 99th American Association of Cancer Research Abstract #2774 (#2774), 4/2008.
14. Gilbert M, Gaupp P, Ictech S, Hess K, Groves M, Levin V, Conrad C, Puduvalli V, Colman H, deGroot J, Hsu S, De Porre P, Yung WKA. A phase I/II study of Temozolomide (TMZ) and the farnesyltransferase inhibitor (FTI), Tipifarnib (Zarnestra, Zar) in recurrent glioblastoma (GBM). Neuro-Oncology:MA-34, 12/2007.
15. Alonso MM, Gomez-Manzano C, Xu J, Piao Y, Jiang H, Yung WKA, Lang F, Fueyo J. Adenoviruses Downmodulate MGMT Increasing Sensibility of Brain Tumor Stem Cells to Temozolomide: A Mechanistic Study. Neuro-Oncology, 12/2007.
16. Koul, Dimpy, Shen R, Edge J, Kondo Y, Webb D, Bankson J, Ronen SM, Lu Y, Powis G, Kirkpatrick DL, Yung WKA. Cellular and in vivo activity of a new PI3K inhibitor-PX866 for treatment of Human Glioblastoma. Neuro-Oncology:ET-28, 12/2007.
17. Alonso MM, Gomez-Manzano C, Xu Y, Piao Y, Jiang H, Yokoyama T, Yung WKA, Lang F, Fueyo J. . Delta-24-RGD in Combination with RAD001 Induces Autophagic Cell Death and 80% of Long Term Survivors. Neuro-Oncology, 12/2007.
18. deGroot J, Lu Li, Yung WKA. Mechanisms of AMPA receptor mediated invasion. Neuro-Oncology:IN-08, 12/2007.
19. Wen P, Puduvalli V, Kuhn J, Reid J, Cloughesy T, Yung WKA, Drappatz J, Lamborn K, Gilbert M, Butowski N, Levin V, Chang S, Kesari S, Robbins HI, McGovern R, Richon V, Frankel S, Ames M, Zweibel J, Prados M. Phase I study of Vorinostat (Suberoylanilide Hydroxamic Acid (SAHA) in combination with Temozolomide in patients with malignant gliomas (NABTC 04-05). Neuro-Onology:MA-13, 12/2007.
20. Popoff S, Aldape K, Wong S, Conrad C, Lang F, Sai K, Yung WKA, Priebe W, Colman H. Regulation of glioblastoma stem cell self-renewal by stat3. Neuro-Oncology:SC-18, 12/2007.
21. Conrad C, Maher E, Cloughesy T, Fink K, Priebe W, Madden T, Meyer C, Foster P, Groves M, Gilbert M, Levin V, Puduvalli V, Colman H, Yung WKA. Results of a phase I trial with the novel anthracycline derivative RTA-744 in patients with recurrent primary brain tumors. Neuro-Oncology:MA-33, 12/2007.
22. Penas-Prado M, Puduvalli V, Groves M, Conrad C, Gilbert M, Levin VA, Yung WKA. Temozolomide plus 13-Cis-Retinoic Acid (TMZ/CRA) as first line chemotherapy for newly diagnosed glioblastoma multiforme (GBM): A retrospective study. Neuro-Oncology:MA-31, 12/2007.
23. Conrad CA, Maher, E, Cloughesy T, Groves M, Gilbert M, Madden T, Levin V, Priebe W, Meyer C, Yung W. Final results of a phase I trial with novel anthracycline derivative RTA-744 in patients with primary brain tumors. Proceedings of the 43rd Annual ASCO Meeting Abstract # 2062, 24(18S):Part I/II:90s, 6/2007.
24. Robins HI, Wen PY, Chang SM, Kuhn J, Lamborn K, Cloughesy T, Gilbert MR, Yung WK, Dancey J, Prados MD. Phase I study of erlotinib and CCI-779 (temsirolimus) for patients with recurrent malignant gliomas (MG) (NABTC 04-02). Proceedings of the 43rd Annual ASCO Meeting Abstract #2057, 24(18S):Part I/II:89s, 6/2007.
25. Wen PY, Puduvalli V, Kuhn J, Reid J, Cloughesy T, Yung WA, Chang SM, Robbins HI, McGovern R, Ames M, Prados MD. Phase I study of vorinostat (suberoylanilide hydroxamic acid) in combination with Temozolomide (TMZ) in patients with malignant gliomas (NABTC 04-03). Proceedings of the 43rd Annual ASCO Meeting Abstract # 2039, 24(18S):Part I/II:84s (#2039), 6/2007.
26. DeGroot JF, Gilbert MR, Hess KR, Hanna T, Groves M, Conrad C. Aldape K, Colman H, Puduvalli V, Yung WA. Phase II study of combination Carboplatin and erlotinib in patients with recurrent glioblastoma multiforme. Proceedings of the 43rd Annual ASCO Meeting Abstract # 2024, 24(18S):Part I/II:81s (#2024), 6/2007.
27. Grewal J, Groves MD, Bekele BN, Yung WA. The role of HER2/neu, estrogen, and progesterone receptor status in the risk of survival of breast cancer leptomingeal metastasis. Proceedings of the 43rd Annual ASCO Meeting Abstract # 1152, 24(18S):Part I/II:604s, 6/2007.
28. Liu TJ, LaFortune T, Yung WKA, Maira SM, Stauffer F, Garcia-Echevrria C. A novel PI3K inhibitor elicits multifaceted antitumor activities in human gliomas. Proceedings of the American Association for Cancer Research:Abstract # 4878, 4/2007.
29. Yuji P, Jiang H, Xu J, Alonso, Lee O, Conrad C, Yung A, Gomez-Manzano C, Fueyo J. Delta24-RIVER oncolytic adenovirus-targeting mutant-EGFR glioma cells. Proceedings of the American Association for Cancer Research (AACR) Annual Meeting Abstract #3297, 4/2007.
30. Koul D, Shen R, Edge J, Ivado E, Kondo Y, Powis G, Kirkpatrick L, Yung WKA. Targeting PI3K in human glioblastoma with PX-866, a small molecule PI3K inhibitor. Proceedings of the American Association for Cancer Research Abstract #278, 4/2007.
31. Jiang H, Lee OH, Aoki H, Kondo S, Lang FF, Kondo Y, Yung WKA, Fueyo J. Delta-24-RGD induces autophagy in cancer stem cells. Neuro-Oncology 8(4):413, 2006.
32. Pelloski CE, Zhang L, Lin E, Bahr K, McDonald JM, Yung WKA, Colman H, Woo SY, Heimberger AB, Suki D, Prados M, Chang S, Barker III F, Buckner JC, Ballman KV, Furth AF, James CD, Aldape KD. EGFRvIII status defines distinct subtypes of glioblastoma: An analysis of 649 cases. Neuro-Oncology 8(4):462, 2006.
33. Jiang H, Olson MV, Xu J, Lee O-H, Piao Y, Yung WKA, Fueyo J. Exportin 1-mediated nuclear export of adenovirus E1A protein: A novel target for generation of oncolytic viruses. Proceedings of the American Association for Cancer Research (AACR) 97th Annual Meeting 47:702, (#2981), 2006.
34. Mayes DA, Wu X, Liu TJ, Yung WKA, Zhou YH. PAX6 alone and synergistically with PTEN suppresses the expression of vascular endothelial growth factor in glioblastoma cells. Proceedings of the American Association for Cancer Research (AACR) 97th Annual Meeting 47:249, #1057 (#1057), 2006.
35. Mayes DA, Hu Y, Teng Y, Wu X, Panda K, Liu L, Siegel E, Tan F, Yung WKA. PAX6 suppresses the invasiveness of glioblastoma cells and the expression of the matrix metalloproteinase 2 gene. Neuro-Oncology 8(4):434, 2006.
36. Wen PY, Chang SM, Kuhn J, Lamborn K, Robins HI, Cloughesy T, Gilbert MR, Yung WKA, Mehta M, DeAngelis LM, Abrey LE, Kesari S, Drappatz J, Lassman AB, Dancey J, Prados MD. Phase I study of erlotinib (Tarceva) and temsirolimus (CCI-779) for patients with recurrent malignant gliomas (NABTC 04-02. Neuro-Oncology 8(4):454, #TA-65, 2006.
37. Wen PY, Yung WKA, Lamborn K, Cloughesy T, DeAngelis LM, Fine HA, Chang SM, Robins HI, Fink K, Abrey LE, Lassman AB, Mehta M, Kesari S, Kim L, Stiles C, Egorin M, Kaplan R, Murgo A, Prados MD. Phase II study of imatinib mesylate (ST1571) for patients with recurrent meningiomas (NABTC-01-08). Neuro-Oncology 8(4):454, #TA-66, 2006.
38. Puduvalli VK, Giglio P, Groves MD, Hess KR, Gilbert M, Mahankali S, Hsu S, Colman H, Conrad C, Levin VA, Yung WKA. Phase II study of the combination of thalidomide and irinotecan in patients with recurrent anaplastic gliomas not on enzyme inducing anticonvulsants. Proceedings of the 41st Annual Meeting of the American Association of Clniical Oncology (ASCO) 24(18S):1564 (#1564), 2006.
39. Puduvalli VP, Giglio P, Groves MD, Hess KR, Gilbert MR, Mahankali S, Jackson E, Levin VA, Conrad CA, Hsu S, Colman H, Ritterhouse M, Ictech S, Yung WKA. Phase II trial of irinotecan and thalidomide in adult patients with recurrent glioblastoma multiforme. Neuro-Oncology 8(4):450 (#TA-47), 2006.
40. Koul D, Shen R, Edge J, Liu TJ, Powis G, Kirkpatrick DL, Yung WKA. Phosphatidylinositol 3-kinase (PI3K) pathway – A therapeutic target for human glioblastoma. Neuro-Oncology 8(4):414, 2006.
41. de Groot JF, Lu L, Liu TJ, Fuller G, Yung WKA. shRNA knockdown of AMPA receptors inhibits glioma proliferation. Neuro-Oncology 8(4):410, #ET-06, 2006.
42. Jiang R, Choi W, Yung WKA, Gerner E, Hamilton SR, Zhang W. Spermine analog N1, N11-diethylnorspermine inhibits mTOR-regulated protein initiation and causes anoikis in glioblastoma cells. Neuro-Oncology 8(4):413, 2006.
43. Liu TJ, LaFortune T, DeGroot JF, Yung WKA. Synergistic therapeutic potential of inhibiting mTOR and IGF-IR pathways. Neuro-Oncology 8(4):415, 2006.
44. Raj VR, Griffin S, Teng Y, Hess KR, Yung WKA, Linskey ME, Zhou YH. The expression of ASPP2, BCCIP, BIRC5, TP53 in glioma: Correlation with p53 mutation and tumor grade. Neuro-Oncology 8(4):424, 2006.
45. Olson MV, Johnson DG, Aldape KD, Fuller GN, Jiang H, Yung WKA, Guha A, Gomez-Manzano C, Fueyo-Margareto J. Transgenic mouse model provides the first direct evidence supporting the oncogenic role of E2F1 in brain. Proceedings of the American Association for Cancer Research (AACR) 97th Annual Meeting 47:643, #2735, 2006.
46. Clarke JL, Ennis MM, Yung WK, Chang SM, Wen PY, Cloughesy TF, DeAngelis LM, Robins HI, Lieberman FS, Fine HA, Abrey L, Gilbert MR, Mehta M, Kuhn JG, Aldape KD, Lamborn KR, Prados MD, NABTC. Surgery at recurrence, prognosis for glioblastoma. Neuro-Oncology. Submitted.

Book Chapters

1. Gomez-Manzano C, Lee O-H, Xu J, Fueyo J, Yung WKA. Neovascularization of malignant gliomas. In: Molecular Neuro-Oncology: Gliomas Methods and Protocols. Ed(s) W Debinski and Y Gillespie. Humana Press: Totowa NJ. In Press.
2. de Groot J, Yung WKA. Small molecule based therapies. In: Neuro-Oncology: The Essentials. Ed(s) Bernstein & M. Berger. Thieme Publishers: New York NJ. In Press.
3. Hsu S, Yung WKA. Tumors of the nervous system. In: MD Anderson Manual of Medical Oncology. Ed(s) CA Koller. McGraw-Hill. In Press.
4. Janus TJ, Yung WKA. Primary Neurological Tumors. In: Textbook of Clinical Neurology, 3rd. Ed(s) Christopher G. Goetz, M.D. Saunders, an imprint of Elsevier Inc. Philadelphia, PA, 1053-1080, 2007. ISBN: 13:978-1-4160-3618-0.
5. Jiang H, McCormick F, Gomez-Manzano C, Curiel D, Lang F, Yung WKA. Replicating viruses for brain tumor treatment. In: Gene Therapy for Neurological Disorders. Ed(s) PR Lowenstein and MG Castro. Taylor & Francis Group: New York NY, 293-325, 2006.
6. Kyritsis A, Yung WKA. Molecular genetics and tumor suppressor genes in gliomas. In: Cerebral Glioma. 5(2). Ed(s) WKA Yung. Bailliere Tindale: London England, 933-956, 1996.
7. Milosavljevic VP, Conrad CA, Yung WKA. Principles of chemotherapy for adult primary brain tumors. In: Cancer of the Nervous System. Ed(s) PM Black and JS Loeffler. Blackwell Science: Cambridge UK, 1996.
8. Flowers A, Yung WKA. Carcinamatosis meningitis and acute cord compression by tumor. In: Cancer in the Nervous System, 4th. Ed(s) R Johnson, J Griffin. Mosby-Year Book: Philadelphia PA, 227-230, 1995.
9. Yung WKA, Sawaya R, Curran W, Fuller GN. Intracranial metastatic central nervous system tumors. In: Cancer in the Nervous System. Churchill Livingstone: New York NY, 1995.
10. Levin VA, Yung WKA. Chemotherapy: Current and future role and expectations. In: Malignant Cerebral Glioma. Chapter 15. Ed(s) MLJ Apuzzo. American Association of Neurosurgeons: Philadelphia PA, 207-216, 1990.
11. Griem JL, Yung WKA, Marks JE, Steward W, Mullen FJ. Treatment of glioblastoma multiforme. In: Tumors of the Nervous System. Ed(s) HG Seydel. John Wiley & Son Inc., 63-68, 1974.

Books (edited and written)

1. Yung WKA. Ed(s) Yung WKA. Bailliere's Clinical Neurology. In: Cerebral Glioma. Bailliere Tindale: London, 1996.

Letters to the Editor

1. Wen PY, Schiff D, Cloughesy TF, Reardon DA, Batchelor TT, Chabner BA, Flaherty K, de Groot JF, Gilbert MR, Galanis E, Chang SM, Schwartz GK, Peereboom D, Mehta MP, Yung WK, Grossman SA, Prados MD, DeAngelis LM. It Is Time to Include Patients With Brain Tumors in Phase I Trials in Oncology. J Clin Oncol 29(24):3211-3, 8/20/2011. e-Pub 7/18/2011. PMID: 21768451.

Grant & Contract Support

Title: SPORE in Brain Cancer
Funding Source: NIH/NCI
Role: Project Leader
Principal Investigator: Lang
Duration: 9/1/2013 - 8/31/2018
 
Title: Preclinical testing of BKM120 mono and combination therapy for gliomas
Funding Source: Novartis Pharmaceuticals
Role: Principal Investigator
Duration: 1/26/2009 - 1/31/2010
 
Title: Deciphering synergistic combinatorial targets in glioblastoma
Funding Source: NIH/NCI
Role: Principal Investigator
Duration: 9/8/2006 - 6/30/2012
 
Title: NABTC Central Operation Grant - Data Management Core
Funding Source: NIH/NCI
Role: Principal Investigator
Duration: 1/1/2004 - 12/31/2008
 
Title: Radiation Therapy Oncology Group
Funding Source: NIH/NCI
Role: Principal Investigator
Duration: 1/1/2004 - 12/31/2008
 
Title: NABTC Clinical Center
Funding Source: NIH/NCI
Role: Investigator
Principal Investigator: Mark R. Gilbert, M.D.
Duration: 2/7/1998 - 12/31/2008

Last updated: 7/12/2016